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ABSTRACT 
PCOS (Polycystic ovarian syndrome), a complex syndrome with endocrine and metabolic 
disorder of chronic anovulation, polycystic ovaries and biochemical and clinical 
manifestations of hyperandrogenism. Hypothalamic - pituitary adrenal axis impairment, 
impaired insulin secretion and action, and ovarian dysfunction are the defects involved in 
pathophysiology of PCOS leads to a metabolic syndrome culminating in serious long-
term consequences such as type 2 diabetes mellitus, endometrial hyperplasia and 
cardiovascular diseases. 
OBJECTIVE 
 An objective of the study is to evaluate the effect of YogaNidra on biochemical changes 
in Polycystic ovarian syndrome women between the age of 18-35 years. 
METHODS 
This study was conducted on 40 adult women between the age of 18-35 years not under 
any medication and fulfilling the Rotterdam criteria and inclusion criteria of this study.  
The study design is experimental pre post, YogaNidra practiced for 40 minutes 6 days a 
week up to 90 days; parameters were recorded at the baseline and also at the end of the 
study. 
 
 RESULT 
Results of this study showed that a significant reduction (P < 0.001) in FBS and PPBS 
and significant reduction (P < 0.0001) in HbA1C, GTT.There was a significant reduction 
(P <0.001) in cholesterol and triglyceride while a significant reduction (p < 0.001) seen 
among HDL, LDL, VLDL and on the anthropometric measurements significant reduction 
were seen in BMI(p < 0.001), Weight (p < 0.001) and WHR (p < 0.02). 
SBP and DBP showed a significant reduction P < 0.0001) after YogaNidra reveals the 
parasympathetic domination over sympathetic nervous system.    
CONCLUSION 
The present study demonstrated the efficacy of YogaNidra on biochemical profiles of 
PCOS women as an effective non pharmacological intervention in addressing the 
psychological and physiological concern of PCOS.  
Key words: YogaNidra, PCOS, Biochemical Changes, HPA Axis, Stress  
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1. INTRODUCTION 
Polycystic ovarian syndrome is a highly prevalent hormonal and metabolic disorder 
which affects 6-8 % (Azziz, R et al., 2005) globally prevalence estimates of PCOS are 
highly variable, ranging from 2.2% to as high as 26%. (Michelmore et al., 1999) 
PCOS has significant and diverse clinical implications including reproductive 
(anovulation, irregular menstrual cycle, infertility, hyperandrogenism and hirsutism), 
metabolic (insulin resistance, impaired glucosetolerance, type-2 Diabetes Mellitus  
(DM), Cardiovascular Disease (CVD),Psychological features anxiety, depression, 
worsened the quality of life. (Teede et al., 2010) 
According to ESHRE / ASRM (European Society for Human Reproduction and 
Embryology/American Society for Reproductive Medicine) consensus conference on 
PCOS held in Rotterdam in 2003, PCOS was defined as at least 2 out of three 
following abnormalities. 
(a) Oligo and/or anovulation, 
(b) Clinical and/or biochemical sign of hyperandrogenism (hirsutism and/or acne or 
increased androgens levels)   
(c) Detection of polycystic ovaries by ultrasound and presence of 10 or more cyst of 
2-10mm in diameter in each ovary and absence of other endocrine conditions such as 
thyroid disorder, Cushing’s syndrome, congenital virilizing adrenal hyperplasia or 
hyperprolactinemia.(Rotterdam ESHRE / ASRM - Sponsored PCOS Consensus 
Workshop Group, T.R.E.A., 2004. Revised 2003) 
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PCOS pathophysiology involves primary defects in the hypothalamic–pituitary 
adrenal axis, insulin secretion and action, and ovarian function (Diamanti-
Kandarakis.E et al., 2006, Shannon.M and Wang.Y 2012) 
 Stress is a ‘stimulus to produce disequilibrium in the homeostasis of 
physiological systems’ resulting from a variety of stressors. The neuroendocrine 
changes associated stress can interpret the signals into pathophysiological alterations. 
(Sridhar GR and Madhu K 2002) 
The hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system 
(SNS) are triggered as a response to a stressor leading to a cascade of physiological, 
behavioral, and psychological effects, primarily as a result of the release of cortisol 
and catecholamines (epinephrine and norepinephrine).  
Due to repeated firing of the HPA axis and SNS, the system gets de-regulated, leading 
to diseases such as autoimmune disorders, obesity, diabetes, substance abuse, 
depression, and cardiovascular disease. (Sterling P 2004, McEwen BS 2000) 
Stress leads to increased levels of hormones like glucagon, cortisol, growth hormone, 
catecholamines,Corticotrophin Releasing  Hormone (CRH), prolactin, leptin, 
neuropeptideY resulting in  hyperglycemia which leads to diabetes. Bjorntop 
postulated that stress plays a role in diabetogenesis through activation of sympathetic 
nervous system following stress and leads to a series of hormonal changes leading to 
obesity and hence diabetes. Psychosocial stress may trigger the onset of visceral 
obesity and metabolic syndrome. 
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Central android obesity and peripheral gynoid obesity is associated with differential 
regulation of HPA and also targets metabolically important tissues such as liver and 
visceral fat. Chronic psychological stress was correlated with prevalence of type 2 
diabetes mellitus and with visceral adiposity. The numbers of stressful events were 
positively associated with the prevalence of newly diagnosed diabetes. (Thangasami 
S.R.et al., 2015) 
The association between insulin resistance and reproductive abnormalities with 
clinical hyper-androgenism in a woman was first demonstrated by Achard and Thiers 
in the “diabetes of bearded woman.” The link of PCOS with insulin resistance was 
subsequently established by clinical studies characterizing the profound insulin 
resistance in obese and lean PCOS patients. (Diamanti-Kandarakis 2006) 
Proven that hyperinsulinemia aggravating ovarian production of androgen.Among 
PCOS women 70% would be of Insulin Resistance (IR) and 10% would be Diabetic. 
(Freeman, R.Pand Rosenbloom, R., E.2010, Farrell.K. and Antoni.M.H 2010, 
Ovalle.F and Azziz, R 2002) 
PCOS is commonly associated with glucose metabolism abnormalities and is an 
independent risk factor for the development of diabetes.Impaired glucose tolerance, 
measured by oral glucose tolerance test, may approach 30–40% in obese populations 
with PCOS. (Legro.R.S. et al., 1999, Ehrmann.D.A.et al., 1999) 
The association between PCOS and an increased rate of incident diabetes remained 
even in women with a BMI of less than 25. (Wang 2011) 
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IR with elevated circulating insulin levels induces unfavorable changes in the lipid 
metabolism and increased androgen production from the theca cells.Androgen excess 
may lead to dyslipidemia and central distribution of fat (android pattern).In obese 
women, excess insulin and androgens may contribute to the development of the PCOS 
and metabolic syndrome. (Eckel.R.H. 2005) 
The android pattern of fat distribution could be the result and also the cause for 
hyperandrogenism, setting up a vicious circle of hyperinsulinism, hyperandrogenism, 
central adiposity and metabolic abnormalities. (Barber.T.M et al., 2006) 
Modern neurophysiologists have been able to demonstrate an obvious relationship 
between the body and the brain which was first recognized by the ancient yogis 
thousands of years ago. Using stimulating electrodes to probe the brain surface, 
neurosurgeons have shown that each part of the body is precisely mapped out along 
the surface of the central gyrus or fold of the sensory motor cortex of the brain. 
YogaNidra is a systemic method. YogaNidra was found and formulated by Swami 
Satyananda Saraswati of Bihar school of yoga. In yogic system, YogaNidra is 
considered as a form of rajayoga, YogaNidra belongs to the higher stages of raja yoga, 
since it is essentially a method of pratyahara - fifth stage of patanjali ashtanga yoga. 
(Swami Satyananda Saraswati, Yoganidra 2001) 
Chapter four of Hatha Yoga Pradipika also speaks of YogaNidra. (Swami. S.S. 
Hathayogapradipika, 1998)    
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In Hatharathnavali, YogaNidra is said as an asana, where in the legs are wound around 
the neck and hands are tied on the back and lied down. This is said to improve the 
positive health. (Srinivasa yogi, Hatharathnavali.2009) 
During the practice of YogaNidra one appears to be asleep but the consciousness is 
functioning at deeper level of awareness, more  efficient and effective in therapeutic 
applications also in many disease conditions.YogaNidra is a systemic method of 
inducing complete physical, mental and emotional relaxation.YogaNidra practice was 
helpful in patients with hormonal imbalances such as dysmenorrhea, oligomenorrhea, 
menorrhagia, metrorrhagia and hypomenorrhea ( Rani.M et al., 2013,Rani.K 2016) 
for diabetes – blood glucose level (Amita.S et al., 2009), Stress, anxiety and 
depressive symptoms (Singh.U et al., 2012, Rani.K et al., 2011, Rani.K et al.,2016) 
and also cardio vascular diseases. 
     YogaNidra appears to regulate hypothalamus,in a way resulting in decreased 
sympathetic (excitatory) nervous activity and increased parasympathetic (inhibitory) 
function (Satyananda.S. 2009) there by YogaNidra reduces the stress (Kumar.K 
2008), oxidative stress, chronic inflammation, insulin resistance and it also reduce 
hyperinsulinaemia, increases SHBG thereby reducing the androgen level through 
regulating the hypothalamic pituitary ovarian axis regulate the SNS and hypothalamao 
pituitary adrenal axis, can prevent and reduce the consequences of PCOS also 
effective in treating the long term consequences of diabetes mellitus, cardiovascular 
diseases, and dyslipidemia. 
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Many studies available in yoga for PCOS as an effective management as a lifestyle 
modification and also a form of exercise, but there is a lacuna in effect of YogaNidra 
on PCOS patients. So the present study was planned to assess the effect of YogaNidra 
practice on biochemical changes in PCOS patients. 
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2. AIMS AND OBJECTIVES  
Aim: 
• To evaluate the effect of YogaNidra on Blood glucose level, Lipid profile, 
 BMI, Waist Hip Ratio and Blood Pressure in Polycystic Ovarian syndrome 
 women aged between 18-35 years. 
 Objectives: 
Primary objective(s): 
• To assess and compare blood glucose levels in PCOS before and after 12 
weeks of YogaNidra 
• To assess and compare lipid profile in PCOS before and after 12 weeks of 
YogaNidra 
Secondary objective(s): 
• To evaluate the changes in the Body Mass Index (BMI) before and after 12   
 weeks of YogaNidra 
• To evaluate the changes in the Waist Hip Ratio (WHR) before and after 12 
 weeks of YogaNidra 
• To evaluate the changes in the Blood Pressure (systolic and diastolic blood 
 pressure) before and after 12weeks of YogaNidra. 
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3. REVIEW OF LITERATURE 
3.1. POLYCYSTIC OVARIAN SYNDROME 
Polycystic ovarian syndrome (PCOS) is a multifactorial, heterogeneous, complex 
genetic, endocrine and metabolic disorder, diagnostically characterized by chronic 
anovulation, polycystic ovaries and biochemical and clinical manifestations of 
hyperandrogenism. It has a tremendous negative impact on the physiology and 
metabolism of the body as it may evolve into a metabolic syndrome with insulin 
resistance, hyperinsulinemia, abdominal obesity, hypertension and dyslipidemia 
presenting as frequent metabolic traits and culminating in serious long-term 
consequences, such as type 2 diabetes mellitus, endometrial hyperplasia and 
cardiovascular disease. (Diamanti Kandarakis 2006)  
PCOS has significant and diverse Clinical implications including 
 Reproductive    (anovulation,irregularmenstrualcycle,infertility, 
hyperandrogenism and hirsutism), 
 Metabolic   (insulin resistance, impaired glucose tolerance, type -2 Diabetes 
Mellitus (DM), Cardio vascular Disease (CVD),  
 Psychological features   (anxiety, depression, worsened the quality of life). 
(Teede et al., 2010) 
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3.1.1   CLINICAL FEATURES OF PCOS 
PCOS is most simply defined as the presence of hyperandrogenism (clinically and/or 
biochemically) and/or chronic anovulation in the absence of specific adrenal and/or 
pituitary disease. (Dunaif A 2001) 
Table 1. Clinical features of polycystic ovary syndromes 
 Oligomenorrhea / amenorrhea 
 Infertility/first trimester miscarriage 
 Obesity 
 Hirsutism 
 Acne 
 Acanthosis nigricans 
 Male pattern alopecia 
Table.1 Outlines the clinical features of PCOS. 
Hyperandrogenism may present clinically as hirsutism, acne and / or male pattern 
alopecia.Hirsutism can be defined as the growth of coarse hair on a woman in a male 
pattern (upper lip, chin, chest, upper abdomen, back etc.).This is to be distinguished  
from hypertrichosis that involves a more uniform, whole body distribution of fine hair. 
Acne related to hyperandrogenism may be difficult to distinguish from normal 
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pubertal acne in an adolescent with PCOS though pubertal acne in general is twice as 
prevalent in adolescent males versus females and males are more likely to have severe 
disease. (Barth JH and Clark S 2003)  
 The severity of any of these manifestations is highly variable and may depend on 
genetic and ethnic differences in the sensitivity to the effects of androgens. The 
presence of virilization (clitoromegaly, deepening voice, increased musculature, or 
rapidly progressive hirsutism or alopecia), however, is not a feature of PCOS, but 
instead of more severe hyperandrogenism.  
Chronic anovulation often presents as oligomenorrhea, amenorrhea, dysfunctional 
uterine bleeding, and/or infertility. Interestingly however around 20% of patients with 
PCOS may describe normal menstrual cycles. (Conway GS et al., 1989) 
Often, but not always, menstrual abnormalities are long-standing, even since 
menarche. Other women may only develop menstrual problems later in life, perhaps 
after significant weight gain. Furthermore, primary amenorrhea is possible although 
not common. 
When clinically evaluating a patient for the possibility of PCOS, it is also important to 
search for signs of Insulin resistance ( IR).Upper-body obesity is a key component of 
the IR syndrome.(Expert Panel on Detection, Evaluation, and Treatment of High  
Blood Cholesterol in Adults. (NCEP) (Adult Treatment Panel III) 2001) 
Obesity is not required for the diagnosis of PCOS with perhaps only 35% to 50% of 
these patients being obese (Knochenhauer ES et al., 1998, Pasquali R et al., 1993) 
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Acanthosis nigricans on physical examination is a sign of IR.A personal or family 
history of type 2 diabetes mellitus or gestational diabetes mellitus or the presence of 
hypertension should also be sought in the evaluation. The criteria for diagnosis of the 
Insulin resistance in women should be evaluated in all patients. (Table.2) (De Groot 
LJ 2000) 
Table .2. Diagnostic criteria for the insulin resistance syndrome in women. 
Any three or more of the following: 
Waist circumference MEN        ≥  102cm,  WOMEN   ≥ 88cm 
Triglycerides > 150 mg/dL 
HDL-cholesterol MEN     <   40 mg/ dL, WOMEN  <   50 mg/ dL 
Blood pressure ≥ 130/85 mm 
Fasting glucose >100 mg/Dl 
After PCOS is diagnosed, studies show that more than 50% of patients develop 
prediabetes or diabetes, and there is an increased risk of myocardial infarction (MI), 
dyslipidemia, hypertension, anxiety, depression, endometrial cancer, and sleep apnea. 
Moreover, pregnant women with PCOS should be informed of the increased rates of 
miscarriage, gestational diabetes, pre-eclampsia, and premature delivery    
(Hurd.W.W et al., 2011) 
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3.1.3. DIAGNOSTIC CRITERIA FOR PCOS 
Diagnostic criteria for PCOS have been offered by three groups:  
Table.3 Criteria for the diagnosis of polycystic ovary syndrome 
NIH/NICHD 1992 
ESHRE/ASRM (Rotterdam 
criteria) 2004 
Androgen Excess Society 
2006 
Exclusion of other androgen 
excess or related disorders 
Exclusion of other androgen 
excess or related disorders 
Exclusion of other androgen 
excess or related disorders 
Includes all of the following: Includes two of the following: Includes all of the following: 
• Clinical and/or biochemical 
hyperandrogenism 
• Clinical and/or biochemical 
hyperandrogenism 
• Clinical and/or biochemical 
hyperandrogenism 
• Menstrual dysfunction •Oligo-ovulation or 
anovulation 
• Polycystic ovaries 
• Ovarian dysfunction and/or 
polycystic ovaries 
 
Abbreviations: ESHRE/ASRM, European Society for Human Reproduction and 
Embryology/American Society for Reproductive Medicine; NIH/NICH, National 
Institutes of Health/National Institute of Child Health and Human Disease. 
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The National Institutes of Health/National Institute of Child Health and Human 
Disease (NIH/NICHD); (Zawadski JK and Dunaif A 1992),the European Society for 
Human Reproduction and Embryology/American Society for Reproductive Medicine 
(ESHRE/ASRM); (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus 
Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health 
risks related to polycystic ovary syndrome. (Fertil Steril. 2004) and the Androgen 
Excess and PCOS Society. (Azziz R E et al. 2006).These criteria are summarized in 
Table 3. 
3.1.4    INVESTIGATIONS AND ASSESSMENT IN PCOS 
There is no single diagnostic test for PCOS. Key investigations include prolactin and 
thyroid stimulating hormone to exclude other disorders and testosterone, SHBG and 
free androgen index to assess androgen status. (Norman RJ et al., 2007) 
Investigations include a pelvic ultrasound for ovarian morphology and endometrial 
thickness. An oral glucose tolerance test (rather than fasting glucose) and lipid profiles 
are appropriate in all women at diagnosis and 1 to 2 yearly after this, where women 
are overweight or have an increased risk of DM2 (for example, family history of DM 
2 in first-degree relatives, increased age or high-risk ethnic group).As noted, insulin 
levels should not be measured in clinical practice because of assay variability and 
inaccuracy. Metabolic syndrome and abnormal glucose metabolism best reflect insulin 
resistance in this population. (Teede et al., 2010) 
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3.2.    PATHOPHYSIOLOGY OF PCOS 
The pathophysiology of PCOS involves primary defects in the hypothalamic–pituitary 
axis, insulin secretion and action, and ovarian function. (Diamanti-Kandarakis.E et 
al., 2006, Shannon.M and Wang.Y 2012) 
3.2.1   ROLE OF HYPOTHALAMIC PITUITARY ADRENAL AXIS (HPA) IN 
PCOS 
Adrenal steroidogenesis is under the control of the hypothalamic - pituitary - adrenal 
(HPA) axis. Furthermore, metabolic factors including insulin and obesity-related 
signals may play a role in the regulation of both enzymes involved in the steroid 
genetic pathways, as well as in the regulation of the HPA axis. 
 In women with the polycystic ovary syndrome (PCOS), cortisol production rate is 
probably normal, although adrenal androgens can be overproduced in a subset of 
affected women.  
Cortisol metabolism and regeneration from inactive glucocorticoids can also be 
disrupted in PCOS, thereby contributing to determining an adrenal hyperandrogenic 
state. Finally, over activity of the HPA axis may be related to the high prevalence of 
psychopathological and eating disorders in women with PCOS, implying a 
maladaptive allostatic load in the adaptive mechanisms to chronic stress exposure. 
Metabolic abnormalities that may be very common in women with PCOS, particularly 
insulin resistance and obesity. Insulin is a true gonadotropic hormone that synergizes 
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with the luteinizing hormone (LH) in the regulation of ovarian steroidogenesis 
(Nestler JE 2008)
 
It may amplify ovarian androgen production rates, thereby representing a triggering 
factor in the pathogenesis of hyperandrogenism. (Ehrmann DA 2005) 
 
 In addition, insulin negatively regulates the synthesis of the major carrier protein of 
androgens, the sex-hormone-binding globulin, and therefore reduces circulating sex-
hormone-binding globulin levels that, in turn, increase the availability of free 
testosterone in peripheral tissues and cells (Ehrmann DA. 2005)  
Hyperandrogenism, in turn, contributes to the generation of insulin resistance through 
the stimulation of lipolysis, and therefore the increased blood availability of free fatty 
acids and the modification of muscle–skeletal structure and metabolic activity   
(Pasquali R. 2006)
 
Obesity may also play an important role in the pathophysiology of PCOS; therefore, 
obesity per se represents a condition of sex-hormone imbalance in women. In fact, 
testosterone production rate can be significantly increased whereas its metabolic 
clearance rate remains unchanged, and the availability of free testosterone may 
increase along with the production rate of estrogens (Pasquali R 2006)  
In addition, the presence of obesity implies an important additional contribution in 
determining the insulin-resistant states and in increasing blood insulin concentrations   
(Morales AJ et al., 1996) Finally, lipid soluble steroids, including androgens, can be 
stored in the adipose tissue, where concentrations may be higher than in the blood, 
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thereby determining that the steroid pool in obese subjects is greater than that in 
normal-weight individuals. In addition, steroids are actively metabolized or 
interconverted in the adipose tissue, because of the presence of steroidogenenic 
enzymes, such as 3b-dehydrogenase, 17b-hydroxydehydrogenase and the aromatase 
system. Alterations in these metabolic pathways may contribute to increased androgen 
peripheral production rates in obese women with PCOS. In turn, androgens may also 
promote the differentiation of preadipocytes into mature adipocytes, particularly in the 
visceral fat. (Pasquali R 2006) 
 
3.2.2. CORTISOL PRODUCTION & THE HYPOTHALAMIC – PITUITARY - 
ADRENAL AXIS IN PCOS 
The glucocorticoid hormones - cortisol (in humans) and/or corticosterone (in animals) 
- are secreted in the adrenal glands under the control hypothalamic structures and the 
pituitary gland, which form the structural organization of the hypothalamic - pituitary 
- adrenal (HPA) axis.  
In the hypothalamic areas, the cascade is in turn chiefly regulated by the corticotropin-
releasing hormone (CRH) and arginine-vasopressin, (Lightman SL 2008) whose 
release activates pro-opiomelanocortin in anterior pituitary corticotroph cells and the  
release of ACTH into peripheral blood, from where it targets receptors in the adrenal 
cortex to release glucocorticoid hormones. 
In the hypothalamus, the parvocellular cells of the paraventricular nucleus of the 
hypothalamus are the major information junction for the neuroendocrine response to 
both internal and external excitatory stimuli. (Herman JP et al., 2003) 
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There is a hierarchical organization of the responsive neurocircuitries upon the 
paraventricular nucleus, which is capable of integrating information from multiple 
limbic sources with internally generated and peripherally sensed information, thereby 
tuning the relative activity of the adrenal cortex. (Herman JP et al., 2003)  These 
circuits are particularly involved in the response to physical and psychological stress, 
both acute and chronic. In most organisms the system efficiently modulates the HPA 
axis in accordance with needs; however, there is a considerable individual variation in 
the HPA response disposition and some influence of genetic factors and early-life 
experience. (Herman JP et al., 2003) Importantly, the organization of the HPA axis 
is under the control of sex hormones, thereby explaining some physiological and 
pathophysiological differences between the sexes in its regulation and activity. (Viau 
V 2002, Williamson M et al., 2005)  
3.2.3. DYNAMIC TESTS ASSESSING THE ACTIVITY OF THE HPA AXIS IN PCOS 
There are only a few studies that have investigated the functioning of the adrenals 
following neuropeptide administration or specific challenges able to evoke primary 
neurooendocrine over activation stimuli. Some evaluated the HPA axis response to 
ovine (oCRH) or human (hCRH) stimulation at different doses in PCOS. 
 Lanzone et al. found that both ACTH and cortisol response to hCRH were markedly 
greater and more prolonged in women with PCOS as compared with controls. Later, 
the same group found that after 6 weeks of treatment with a somatostatin analog, 
octreotide treatment (100 mg subcutaneously, twice daily),  
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ACTH and cortisol response significantly decreased in women with PCOS, and no 
difference was present with respect to controls, suggesting that a hyperfunction of the 
HPA axis secondary to central and/or peripheral somatostatinergic activity in these 
women might exist. (Lanzone A et al., 1997)  
Another study (Azziz R et al., 1997) investigated whether women with PCOS 
characterized by DHEAS excess differed, with respect to those with normal DHEAS 
blood values or controls (matched for age and BMI), in the response to oCRH 
stimulation (1 mcg/kg) or an 8-h incremental intravenous stimulation with ACTH (1–
24) at doses ranging from 20 to 2880 ng/1.5 m
2
 × h with a final bolus of 0.25 mg.  
No significant differences in the net maximal response for ACTH, 
dehydroxyepiandrosterone (DHEA), androstenedione or cortisol were observed; 
nonetheless, the net response of the DHEA/cortisol ratio and of the areas under the 
curve for DHEA and the DHEA/cortisol ratio indicated a greater response for PCOS 
women with high DHEAS levels compared with both their counterparts. Moreover, no 
difference in the sensitivity (i.e., threshold or minimal stimulatory dose) to ACTH was 
noted between the groups for any of the steroids measured; however, the average dose 
of ACTH (1–24) required for a threshold response was higher for DHEA than for 
cortisol and androstenedione in all groups. In addition, no difference in mean 
responsivity (slope of response to incremental ACTH stimulation) was observed for 
DHEA and cortisol between the study groups, whereas the responsivity of 
androstenedione was higher in PCOS women with high DHEAS than in those with 
normal DHEAS. Collectively, the data of this complex study seem to support the 
concept that adrenal androgen excess in PCOS patients is related to an exaggerated 
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secretory response of the adrenal cortex (for DHEA and androstenedione), but not to 
an altered pituitary responsivity to CRH or to increased sensitivity of these androgens 
to ACTH stimulation. However, the data could not define whether the increased 
responsivity to ACTH for these steroids might be secondary to increased zona 
reticularis mass or to differences in P450c17a activity, particularly of the delta-4 
pathway.  
In this regard, an interesting study (Wu XK et al., 2000) has suggested that, in women 
with PCOS, ovarian hyperandrogenicity may potentially directly contribute to the 
enhanced adrenal P450c17a activity and subsequent delta-4 androgen reserve revealed 
by ACTH (1–24) stimulation, independently of mechanisms regulating adrenal 
cortisol secretion. Intriguingly, this might imply a functional crosstalk between the 
ovaries and the adrenals. A third study evaluating the dynamics of the pituitary–
adrenal hormone response to hCRH in women with PCOS, Kondoh et/al. found that 
plasma ACTH and cortisol response were significantly higher with respect to controls 
only in a subgroup of women with PCOS, and that these women were also 
characterized by higher blood levels of DHEAS, but greater suppression of 
androstenedione following dexamethasone administration. (Kondoh et al., 1999)  
Mechanisms responsible for an increased responsiveness of the HPA axis - which can 
be detected only in specific subsets of women with PCOS - are still unclear, although 
altered somatostatinergic (Lanzone A et al., 1997)
 
 and opioid system  (Fulghesu AM 
et al., 1998, Lanzone A et al.,1996) functions, possibly contributing to a hyperactive 
HPA axis have been suggested.  
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Finally, one study investigated the HPA response to insulin-induced hypoglycemia in 
a small group of women with PCOS and weight-matched controls (Gennarelli G et 
al., 1999)
. 
It was found that, compared with controls; women with PCOS had a 
significantly lower ACTH response, and a quantitatively comparable and more prompt 
cortisol response than the controls, resulting in a higher molar ratio between the 
maximum increments of cortisol and ACTH. Furthermore, a more rapid decline in 
cortisol levels occurs in PCOS than the controls, where as the responses of the 
androgens and intermediate adrenal steroids were similar in both PCOS and control 
women. The findings may suggest an adaptation to increased adrenal reactivity to 
endogenous ACTH in women with PCOS, although this model, used to investigate 
neuroendocrine reactivity, did not show hypersecretion of adrenal androgens and 
revealed no signs of steroid enzyme disturbances. Questions of the extent with 
differences in enzyme activities in the cortisol metabolism contribute to the rise in 
production remain unresolved because a quantitative kinetic model of cortisol 
metabolism is not available.Therefore, understanding the mechanisms responsible for 
altered cortisol and eventually adrenal androgens after stimulatory challenges is still a 
difficult task.In line with these findings, a potential indirect role of nutrients and 
insulin in the regulation of adrenal steroidogenesis has also been suggested by a recent 
study showing that, in women with PCOS, the presence of obesity and insulin 
resistance is associated with lower morning cortisol and DHEAS but increased 
cortisol and DHEA responses during an oral glucose tolerance test. Specifically, those 
women who had higher BMI and lower insulin sensitivity indices also had a higher 
early (at 60 min) response to glucose load and a later lower late nadir (at 180–240 
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min) glucose values. These nadir values were significantly associated with late 
cortisol increase and with higher scores in shakiness, sweatiness, weakness and 
hunger, suggesting the presence of reactive hypoglycemia in these women and, 
therefore, explaining the reactive cortisol increase. (Gurusinghe D et al., 2010) 
Interestingly, this hormonal imbalance in obese insulin resistant and hyperinsulinemic 
patients with PCOS might have important long-term consequences because of 
repeated stimulation of the HPA axis by nutrients. In fact, it is conceivable that 
ingestion of simple sugars can cause even mild postprandial hypoglycemia, thereby 
stimulating secretion of adrenal steroids that, in turn, may favor further weight gain 
and insulin resistance, thus creating a vicious cycle. 
To summarize, all available studies support the possibility that the HPA axis response 
to neuroendocrine stimuli may be altered only in a subset of women with PCOS, in 
whom metabolic factors, such as obesity and insulin excess, may play a role in 
determining abnormalities in the regulation of the adrenal axis.  
3.2.4. THE ROLE OF OBESITY IN MODULATING THE ACTIVITY OF THE 
HPA AXIS IN PCOS 
Obesity represents a potential factor responsible for altered HPA axis functioning in 
PCOS, and this may be supported by the strong association between these two 
disorders and by the fact that the pulsatile and spiky activity of ACTH secretion are 
under the influence of body fat and body composition, as well as age. (Veldhuis JD et 
al., 2009) this may be due to the fact that these confounders were not adequately taken 
into account. In fact, several studies performed in women with different phenotypes of 
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obesity have shown that a dysregulation of the HPA axis may exist in this population, 
particularly those with the abdominal phenotype. (Pasquali R et al., 2008)  
In these women, basal blood levels of ACTH and cortisol are usually normal, as are 
ACTH and cortisol daily rhythms. (Chalew S et al., 1995)  
However, one study performed to investigate the pulsatile secretion of cortisol and 
ACTH during the daytime in women with different obesity phenotypes showed that 
those with visceral obesity had higher ACTH pulse frequency and lower ACTH pulse 
amplitude, particularly in the morning, but similar mean ACTH basal concentrations, 
in comparison with their gluteofemoral type obese counterpart and normal-weight 
controls, (Pasquali R et al., 1998)  suggesting an increased sensitivity of cortisol 
secretion to non-ACTH-dependent pathways, such as the peripheral noradrenergic 
regulatory system, particularly during the zenith phase of the daily rhythm. Several 
other studies used the urinary free-cortisol (UFC) excretion as an integrated 
measurement of daily cortisol excretion rate, and reported higher than normal 24-h 
UFC excretion rates in women with abdominal obesity, and a significant positive 
correlation with the extent of abdominal adiposity. (Pasquali R et al., 1993, Duclos 
M et al., 1999, Epel EE et al., 1999) 
Dynamic studies in which the HPA axis was either stimulated or inhibited provided 
the most convincing evidence for a dysregulation of the system in abdominal obesity. 
They demonstrated higher than normal cortisol responses after laboratory stress tests, 
or after challenges of the HPA axis by administering CRH or arginine-vasopressin 
alone, or in combination (Pasquali R et al., 2006), in women with abdominal obesity 
23 
 
with respect to those with the peripheral phenotype, even regardless of psychiatric 
disorders. (Vicennati V et al., 2000)  
The strong reproducibility of the CRH test among individuals is undoubtedly a 
strength factor supporting the reliability of these data. (Bertagna X et al., 1994) 
Similar differences between abdominal and peripheral obese women have been 
reported by using the ACTH (1–24) stimulatory test, using either maximal or low 
doses. (Pasquali R et al., 1993) 
The suppressive challenge of the HPA axis using low-dose (i.e., ≤0.5 mg overnight) 
dexamethasone provided relatively confirmatory results. A blunted inhibition of 
cortisol secretion, suggesting a reduced sensitivity to inhibition by low-dose 
dexamethasone via downregulation of central glucocorticoid receptors, has been 
reported. (Ljung T et al., 1996)  
Another study, in both obese and normal-weight individuals who randomly 
underwent different low-dose dexamethasone doses showed that, unlike men, with 
increasing amounts of abdominal fat, women tended to show a significant lower 
suppression of blood cortisol levels with respect to that expected on the basis of 
increasing dexamethasone doses) (Pasquali R et al., 2002) further confirming the 
potential impairment of sensitive feedback signals in abdominally obese women. 
The data showed that basal, pulsatile and total cortisol production (expressed per liter 
of distribution volume, per square meter of body surface and as absolute amount per 
24-h) was similar in PCOS patients and matched healthy controls. Accordingly, the 
regularity of cortisol secretion and the diurnal properties or circadian rhythm were 
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identical. However, compared with ten lean control women, mean cortisol production 
per liter of distribution volume was similar in the three groups, but the total 24-hr 
cortisol production was increased in obese control women and PCOS women. These 
data confirm previous studies investigating cortisol secretion in obesity assessed with 
different methods, including isotopic dilution, measurement of UFC and C21 
metabolites that have invariably shown increased cortisol production in obesity. 
(Dunkelman SS et al., 1964, Strain GW et al., 1980, Stewart PM et al., 1999, 
Roelfsema F et al., 2009) 
3.2.5. THE ROLE OF INSULIN ON ADRENAL STEROIDOGENESIS 
Insulin is able to regulate gonadal steroidogenesis in both males (Pasquali R et al., 
1995) and females. (Poretsky L et al., 1994) In women with PCOS, insulin excess 
amplifies ovarian androgen production rates, (Dunaif A et al., 1989) independent of 
changes in gonadotropin secretion and activity. Although earlier studies produced 
conflicting results, (Nestler JE et al., 1987, Stuart CA et al., 1987) 
 
a study 
performed in PCOS women and healthy controls, where LH responses to varying 
doses of gonadotropin releasing hormone (GnRH) during a fixed rate of insulin 
infusion and LH responses to a fixed dose of GnRH during varying doses of insulin 
infusion were investigated, showed that in the latter both basal LH and LH responses 
to GnRH were unaltered by insulin infusion, whereas these measures were reduced 
during insulin infusion in women with PCOS, and that this effect was negatively 
dependent on body weight. (Lawson MA et al., 2008)  
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The role of insulin and other factors, particularly IGFs 1 and 2, in the regulation of 
ovarian theca and granulosa cells has been repeatedly demonstrated by in 
vitro studies performed in animal models and human tissues.  
These studies provided the basis for the role of insulin excess in determining 
increased androgen production and enhanced follicular cyst development in the 
PCOS. (Poretsky L et al., 1999)  
The key enzyme system representing the target of insulin action in the ovaries is 
cytochrome P450c17α, as shown by the increased activity of 17α-hydroxylase and, to 
a lesser extent, of 17, 20-lyase, resulting in excessive ovarian androgen production. 
(Nestler JE 2008)
 
 A more recent study further supported that sustained hyperinsulinemia is capable of 
potentiating gonadotropin-stimulated ovarian androgen steroidogenesis in women 
with PCOS.(Tosi  F et al., 2012)More recent studies provided in vivo data 
demonstrating that, in women with PCOS, a steady state of insulin excess produced 
proof of the concept that hyperinsulinemia is associated with an amplification of the 
17α-hydroxycorticosteroid intermediate response to ACTH stimulation, without 
alterations in serum cortisol or androgen response to stimulation.  
This was demonstrated by evaluating the adrenal steroid response to ACTH (1–24) or 
saline infusion during a 3-h hyperinsulinemic (80 mU/m
2
 × min) euglycemic clamp 
in a group of 21 hyperandrogenic women with PCOS. (Moghetti P et al., 1996).It 
was found that no significant difference in the cortisol, progesterone or 
androstenedione response to ACTH was present between the ACTH and the saline 
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infusion. By contrast, ACTH-stimulated serum 17-hydroxypregnenolone (p < 0.005) 
and 17-hydroxyprogestrone (p < 0.01) were significantly higher during insulin than 
during saline infusion, with a modest but significant increase in serum DHEA during 
hyperinsulinemia.Inaddition, ACTH-stimulated 17 -  hydroxypregnenolone 
/DHEA(p<0.001)and17b-ydroxyprogestrone/androstenedione (p < 0.005) molar ratios, 
indexes of apparent 17, 20-lyase activity, were significantly higher during the clamp 
studies than during saline infusion. These in vivo data therefore support the 
hypothesis that insulin potentiates ACTH-stimulated steroidogenesis, and that this 
effect of insulin is probably to be associated with a relative impairment of 17, 20-
lyase activity. In a more recent study, the same research group provided further 
evidence for the presence of an insulin-mediated dysregulation of adrenal 
steroidogenesis. (Tosi F et al., 2011) 
These findings demonstrate that the decrease of circulating insulin may improve 
adrenal steroidogenesis, possibly through a regulation of peripheral cortisol 
metabolism, rather than affecting cortisol production rate from the adrenals. By 
contrast, studies with metformin have produced disparate results, showing changes in 
the circulating hormones compatible with a significant decrease in the activity of 3b-
hydroxysteroid dehydrogenase in C (Gennarelli G et al., 1999) steroids and in 17b-
hydroxysteroid dehydrogenase after ACTH stimulation in one study, or unaltered 
17b-hydroxyprogesterone and androstenedione responses to ACTH (1–24) 
stimulation in another study suggesting no direct relationship between insulin 
resistance and adrenal P450c17a enzyme dysregulation.( Unlühizarci K et al., 1999) 
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3.2.6. CORTISOL & THE HPA AXIS ACTIVITY & THEIR RELATIONSHIP 
TO STRESS & EATING BEHAVIOR :  IMPLICATIONS FOR THE 
PATHOPHYSIOLOGY OF PCOS  
PCOS is associated with several psychological disturbances and reduced quality of 
life (Benson S et al., 2009) This may reflect the individual discomfort to the 
presence of signs (i.e., hirsutism) and symptoms (i.e., irregular menstruations). 
Obesity itself may have a significant psychopathological impact, and may lead to 
poorer psychological heath by producing body dissatisfaction and lower self esteem. 
(Hill AJ et al., 1998, Johnson F et al., 2005)  
Collectively, these traits may lead to perceived chronic stress and subsequent 
maladaptive response, which per se may play some role in the pathophysiology and 
the development of metabolic alterations often associated with PCOS, and the 
subsequent susceptibility to develop metabolic and cardiovascular diseases.  
A specific phenotype of obesity related to poor coping to a stressful event, which is 
characterized by rapid weight gain and increased daily UFC excretion 
rates.(Vicennati V et al., 2009)   
Given the very high prevalence of obesity and psychopathological traits in women 
with PCOS, the potential association with alterations of the HPA axis, chronic stress 
and eating behavior or nutrient intake should not be underestimated. This first implies 
the knowledge of the physiological interaction between the HPA axis and the 
digestive tract and, second, the interpretation of the neuroendocrine circuits linking 
the activation of the hypothalamic nuclei regulating the HPA axis  and those involved 
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in the regulation of food intake, the reward system and the response to stress. 
(Dallman MF et al., 2004)  
A strong interaction between the HPA axis and the brain - gut axis is well known, 
although much more information is needed to understand the tuned mechanism 
involved in this complex network. (Leal AM et al., 1997)  
 For example, both food intake and the light–dark cycle have been found to represent 
independent synchronizers for the circadian periodicity of cortisol secretion in 
experimental animals. (Ishizuka B et al., 1983)   
All the conditions cited earlier may have some relevance in the development of a 
pathological allostatic load, consistent with a maladaptive response to chronic stress, 
which explains the association between features of PCOS and metabolic 
comorbidities, such as abdominal obesity. This may be partly explained by an 
increased activity of the HPA axis, a key hormonal component of body maladaptation 
to stress. There are no studies focused on the potential role of chronic stress exposure 
in the pathophysiology of PCOS and its metabolic comorbidities. One controlled 
study investigated the neuroendocrine and immune cell response following a public 
speaking test - which has been proved to induce reproducible and pronounced 
responses of the HPA axis as well as changes in cytokine levels – showed that both 
PCOS women and weight-matched controls had comparable increases in state 
anxiety, blood pressure and C-reactive protein levels, whereas ACTH and cortisol, as 
well as heart rate responses, were significantly higher in PCOS women, together with 
a reduced up regulation of IL-6. (Benson S et al., 2009) 
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There are studies focusing on the relationship between psychological distress, hyper 
androgenemia and menstrual disturbances and their association with greater food 
cravings and high fat and sweets in hyper androgenic young women, relatively 
independent of BMI. (Lim SS et al., 2009)  
3.2.6.     GENETICS OF THE HPA AXIS & PCOS 
The molecular basis of genetic variation in the HPA axis activity relates to adrenal 
production of glucocorticoids, their binding to corticosteroid-binding globulin (CBG) 
and consequently their bioavailability and their efficacy on the transduction 
mechanisms. Numerous molecular polymorphisms have been described to contribute 
to physiological as well as to HPA axis-related variations. (Mormede P et al., 2011)  
  Unfortunately, the genetic imprinting of the HPA axis in PCOS has been poorly 
investigated, in spite of the intensive research of genetic factors involved in the 
development of androgen excess and metabolic alterations. (Goodarzi MO et al., 
2011) 
The few available studies suggest that genetic factors may play some potential role in 
the expression of the HPA axis activity in this disorder. One study investigated the 
sibling correlation of ACTH hormone-stimulated steroid hormone levels between 
probands with PCOS and their sisters and found that ACTH log-transformed DHEA 
and cortisol values were significantly correlated between siblings, which supports a 
potential genetic basis of the adrenal androgen excess observed in PCOS. (Goodarzi 
Moet al., 2007)  
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Another study found that, in a large cohort of women with hirsutism, including 45% 
women with PCOS, approximately 20% of women with idiopathic hirsutism and 
PCOS had increased 17-hydroxyprogesterone and cortisol response to ACTH (1–24) 
stimulation, supporting the concept that CYP21-carrier status could not explain the 
observed high prevalence of abnormal ACTH-stimulated adrenal hormone levels. 
(Glintborg D et al., 2005)  
A third study assessed the influence of known functional polymorphisms in genes 
involved in the production, metabolism and signal transduction of steroid hormones 
in a large cohort of women with or without PCOS. (Valkenburg O et al., 2011) This 
study found that the genotype-frequencies were similar in PCOS cases and 
population-based controls, although a possible association between glucocorticoid 
receptor genotype and LH levels was suggested. In fact, the data showed lower LH 
levels in association with glucocorticoid receptor alleles that are known to increase 
receptor sensitivity (rs6195 and rs41423247) and higher LH levels in glucocorticoid 
receptor variants that may inhibit receptor sensitivity (rs6190 and rs6198), supporting 
the concept that these variants may influence gonadotrophin levels in women with 
anovulatory PCOS, through modulation of the function of the hypothalomo–
pituitary–gonadal axis.  
Finally, there are no studies on the genetics of CBG in PCOS, although stress-
induced falls in CBG levels may heighten HPA axis responses and CBG: tissue 
interactions may allow targeted cortisol delivery. There are only preliminary data of 
altered CBG levels in hypertension and in the metabolic syndrome, but the nature of 
these associations is uncertain. (Gagliardi L et al., 2010)  
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The genetics of enzymes involved in the metabolism of cortisol in peripheral tissues 
is discussed in the specific following paragraphs such as infertility, acne, and 
hirsutism, and possibly negative affect as well. 
Cortisol is secreted in response to stressful stimuli in all individuals, and contributes 
to increased visceral fat (Drapeau.V et al., 2003) and increased inflammation. 
(Fried.S.K et al., 1998) 
 This mechanism could be especially problematic in woman with PCOS since they 
have more visceral fat and higher inflammatory markers than normal women, and 
cortisol secretion contributes to hyperandrogenism. Further, a very provocative study 
reported that lean women with a high waist-to-hip ratio (WHR) secrete more cortisol 
following both novel and familiar cognitive laboratory stressors than do lean women 
with a low WHR. (Epel.E.S et al., 2000) 
These results provide evidence that women with a high WHR, unlike those with a 
lower WHR, tend not to adapt even to familiar stressors, suggesting that they are 
much more likely to experience elevated cortisol - and, consequently, increased 
visceral fat - in response to commonly faced stressors. These researchers speculate 
that maladaptive psychological characteristics such as pessimism, negative affect, 
passive coping, and greater threat perception may play a role in the bidirectional 
relationship between cortisol and visceral fat among women with higher WHR. 
The above studies not only illustrate cortisol secretion abnormalities among women 
with PCOS, but also underscore the importance of reducing stress and other 
maladaptive psychological characteristics in the PCOS woman so as to reduce, as 
32 
 
much as possible, an elevated cortisol response and subsequent visceral fat and 
hyperandrogenism. Since treatment with metformin may not affect stress reactivity, 
stress reduction interventions may be important adjunctive approaches when treating 
women with PCOS. 
Another hormone generally elevated among women with PCOS, testosterone, may 
contribute to increased sympathetic nervous system (SNS) activity.A very interesting 
study found that exogenous testosterone administration among healthy young women 
induced cardiac acceleration in response to images of angry faces (Van Honk.J et 
al., 2008)  
Since the majority of women with PCOS have elevated testosterone, it is likely that 
women with PCOS will have an exaggerated sympathetic nervous system response to 
anger and other negative affect, which may exacerbate inflammation.  (Black.P.H et 
al., 2003) 
These findings underscore the importance of stress management interventions among 
PCOS women so as to reduce the adverse physiological changes which can result 
from psychological stress. 
Persistent negative affect and exaggerated SNS activity, then, may exist in the PCOS 
woman partly due to elevated testosterone alone. The relationship between 
testosterone and mood, however, is not entirely clear, as one study demonstrated that 
there is a curvilinear relationship between testosterone levels and depression in 
women with and without PCOS such that the most severe depression was associated 
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with levels below and above the normal female range of testosterone. (Weiner.C.L 
et al., 2004)  
Negative affect and SNS activation may adversely affect these women by 
contributing to cortisol abnormalities and chronically elevated inflammation. 
Normally, inflammation is down-regulated by cortisol, but states of prolonged 
inflammation (likely to exist in PCOS) result in a phenomenon known as 
glucocorticoid resistance. In this state, glucocorticoids are no longer able to suppress 
the production of pro-inflammatory markers (Raison.C.L. and Miller A.H 2003)  
Depression and sleep disorders are quite common among women with PCOS; and 
women with PCOS have seemingly-inherent chronic inflammation (thereby 
rendering them susceptible to glucocorticoid resistance). 
Women with PCOS display enhanced sympathetic nervous system and HPA axis 
activity in response to stressors, which may contribute to increased visceral fat and 
subsequent inflammation. Interrelations among these abnormalities may create a 
negative spiral leading to greater insulin resistance and subsequent 
hyperandrogenism, exacerbating clinical symptoms such as infertility, acne, and 
hirsutism, and possibly negative affect as well. 
3.2.7.   STRESS AND MOOD MANAGEMENT 
Women with PCOS are likely to exhibit exaggerated SNS responses and HPA-axis 
abnormalities to negative stimuli, suggesting that teaching them techniques to better 
manage stressors may offer benefits. In addition to improving mood and decreasing 
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stress, cognitive behavioral approaches, including stress management interventions, 
appear in other populations to be capable of normalizing HPA axis regulation. 
(Antoni.M.H et al., 2000, Cruess.D.G et al., 2000, Phillips.K.M et al., 2008) as 
well as lowering SNS activity. (Antoni.M.H et al., 2000) 
 As such, techniques such as relaxation and cognitive behavioral therapy directed at 
better managing stress may be used to address the cortisol secretion abnormalities 
often present in PCOS women, especially since standard treatment with metformin 
does not appear to affect physiological responses to stress. (Benson.S et al., 2009) 
Stress management approaches may also have the secondary effects of reducing 
hyperandrogenism, as has been demonstrated in women with other conditions. 
(Cruess.D.G. et al., 2001) 
3.2.8.   APPETITE REGULATION 
In addition to insulin, other hormones related to obesity are cholecystokinin, the 
“satiety hormone,” and cortisol. Interestingly, secretion of cholecystokinin is reduced 
among women with PCOS, which causes abnormal appetite regulation, possibly 
leading to overeating and subsequent obesity. (Hirschberg.A et al., 2004) 
Likely partially due to obesity but also seemingly inherent in women with PCOS are 
cortisol level abnormalities; specifically, an increase of peripheral cortisol 
metabolism due to abnormal levels of certain enzymes that metabolize cortisol (i.e., 
5-alpha reductase, 11 beta-hydroxysteroid dehydrogenase). (Barber.T.M et al., 
2006, Rodin.A et al., 1994) 
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This increase in cortisol metabolism may result in a decreased negative feedback 
signal to the HPA axis, thereby maintaining high production of ACTH and, 
consequently, increased production of adrenal androgens, which exacerbates PCOS 
symptoms. (Tsilchorozidou.T et al., 2004)  
Evidence of HPA axis abnormalities among women with PCOS have been 
demonstrated in several studies and these abnormalities cannot necessarily be 
attributed to body fat distribution, obesity, or androgen or insulin levels. (Lanzone.A 
et al., 1995, Carmina.E et al., 1990) 
3.3   INSULIN RESISTANCE AND PCOS 
 Insulin resistance appears to contribute to hyperandrogenism and other gonadotropin 
abnormalities via at least two mechanisms.  
First, high concentrations of insulin reduce circulating SHBG levels, resulting in 
increased bioavailable (free) testosterone, as less SHBG is available to bind with 
testosterone. (Nestler, J.E. et al., 1991) 
Second, high insulin concentrations also stimulate androgen biosynthesis from 
ovaries. (Nestler J.E. et al., 1998) 
Insulin resistance,frequently appearing in PCOS as well, results in a compensatory  
hyperinsulinemia, which augments luteinizing hormone (LH) stimulated androgen 
production, either via its own receptors or via insulin growth factor (IGF-1) 
receptors.Oxidative stress  level is also observed to be significantly correlated with 
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obesity, insulin resistance, hyperandrogenemia, and chronic inflammation. (Nasiri.N 
et al., 2015, González.F. et al., 2012, Federico.A 2007) 
Insulin resistance is believed to play an intrinsic role in the pathogenesis of PCOS. 
The mechanism by which insulin resistance or insulin give rise to oligomenorrhea and 
hyperandrogenemia, however, is unclear. Hyperinsulinemiceuglycemic clamp studies 
have shown that both obese and lean women with PCOS have some degree of insulin 
resistance.Insulin resistance is implicated in the ovulatory dysfunction of PCOS by 
disrupting the hypothalamic pituitary ovarian axis.Given the association with insulin 
resistance, all women with PCOS require evaluation for the risk of metabolic 
syndrome (MetS) and its components, including type 2 diabetes, hypertension, 
hyperlipidemia, and the possible risk of clinical events, including acute myocardial 
infarction and stroke. Obese women with PCOS are at increased risk for MetS with 
impaired glucose tolerance (IGT; 31 to 35%) and type 2 diabetes mellitus (T2DM; 7.5 
to 10%). Rates of progression from normal glucose tolerance to IGT, and in turn to 
T2DM, may be as high as 5 to 15% within 3 years. (Goodman.N.F et al., 2015) 
Numerous studies have documented that insulin resistance is common in both obese 
and lean women with PCOS. (Sharma.S.T. and Nestler.J.E, 2006) 
 In fact, 70% of women with PCOS are insulin resistant (González. F et al., 2006) 
The hyperinsulinemic state present in most women with PCOS appears to play a 
central role in PCOS development and is considered to be the cause rather than the 
result of hyperandrogenism (Tsilchorozidou.T et al., 2004)  
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 Studies supporting this hypothesis reveal that antiandrogen therapy does not improve 
insulin resistance. (Diamanti-Kandarakis et al., 1995) while insulin-sensitizing 
agents (i.e., metformin) not only improve insulin sensitivity but also improve 
menstrual abnormalities and reproductive outcomes in women with PCOS, providing 
indirect evidence of reduced hyperandrogenism. (Moghetti.P et al., 2000) 
As many as 70% of PCOS women are insulin resistant and 10% have DM. (Farrell.K 
and Antoni.M.H 2010, Ovalle.F and Azziz.R 2002) In PCOS women with normal 
glucose metabolism initially, the rate of conversion to abnormal glucose metabolism 
can be 25% over just three years. (Pesant.M.H and Baillargeon.J.P 2011)  
 More alarming, insulin abnormalities are highly prevalent in adolescents with PCOS. 
(Bhattacharya.S.M. and Ghosh.M 2010) The  routine use of OGTT is advocated by 
some in all PCOS women. (Katz.A et. al., 2000) 
In teenagers, abnormalities in glucose metabolism manifest prior to dyslipidemia, 
suggesting that assessment of glucose metabolism is even more important in younger 
women. (Fulghesu.A et al., 2010) 
Approximately 50% to 70% of all women with polycystic ovary syndrome (PCOS) 
have some degree of insulin resistance, and this hormone insensitivity probably 
contributes to the hyperandrogenism that is responsible for the signs and symptoms of 
PCOS.The OGTT is probably the best simple, officebased method to assess women 
with PCOS because it provides information about both insulin resistance and glucose 
intolerance. The diagnosis of glucose intolerance holds greater prognostic and 
treatment implications. (Legro.R.S et al., 2004) 
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A substantial proportion of PCOS patients have abnormalities on the oral glucose 
tolerance testing at the time of diagnosis. When assessed overall (obese and lean 
together) PCOS patients had a 31% rate of impaired glucose tolerance and 7.5% met 
the criteria for type 2 diabetes mellitus. (Legro R et.al., 2004)Prevalence and 
predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in 
polycystic ovary syndrome: a prospective, controlled study in 254 affected women. 
(Legro RS et al., 1999) 
In those with normal glucose tolerance at baseline 17% had developed impaired 
glucose tolerance or type 2 diabetes mellitus over time, while 54% of those with 
impaired glucose tolerance at baseline had progressed to type 2 diabetes mellitus. 
Further support for the high prevalence of abnormal glucose tolerance in PCOS is the 
10-fold increased risk of developing gestational diabetes mellitus compared to the 
general population (baseline risk ~3%). (Glueck CJ et al., 2001) 
Metformin therapy throughout pregnancy reduces the development of gestational 
diabetes in women with polycystic ovary syndrome. (Glueck CJ et al., 2002) 
Lastly, Cibula et al. noted a 4-fold increased prevalence of type 2 diabetes mellitus in 
women with PCOS who had undergone ovarian wedge resection for polycystic 
ovaries some 20 to 40 years earlier compared to a closely matched control population 
(Cibula D 2000) 
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3.4    HYPERANDROGENEMIA 
Hyperandrogenemia is a classical feature of polycystic ovary syndrome (PCOS), and 
70%–80% of women with hyperandrogenemia are diagnosed with PCOS.  
(Nisenblat.V and Norman.R.J 2009) 
Hyperandrogenemia is regarded as the core pathogenesis of PCOS, as PCOS models 
of animals could be established by excess androgen administration (Nisenblat.V and 
Norman. R.J 2009, Masszi.G et al., 2013) For the increased androgen levels in 
PCOS, insulin resistance (IR) is regarded as the primary factor, by compensatory 
hyperinsulinemia. (Bremer.A.A and Miller.W.L 2008) 
 Insulin is reported to stimulate ovarian androgen secretion directly alone and/or 
augment luteinizing hormone-(LH-) stimulated androgensecretion. (Barbieri.R.L et 
al., 1986, Yelich.J.V et al., 1996, Hernandez.E.R et al., 1988) 
In addition, insulin may also enhance the amplitude of gonadotropin-releasing 
hormone- (GnRH-) stimulated LH pulses, decrease hepatic production of serum sex 
hormonebinding globulin (SHBG), and/or decrease insulin-like growth factor binding 
protein-1 (IGFBP-1). (Adashi.E.Y et al., 1981, R.Soldani.A.et al., 1994, Nestler.J.E 
et al., 1991)  
Finally, the availability of free insulin-like growth factor-1 (IGF-1) is increased to 
stimulate androgen production. (      .L et al., 1997, Werner.H et al., 1993) 
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3.4.1.   CLINICAL HYPERANDROGENEMIA 
Hirsutism—Hirsutism in females is defined as the presence of terminal hairs on the 
face and/or body in a male-type pattern, and it affects 65–75% of the population with 
PCOS. (Azziz.R et al., 2006) 
Hirsutism is determined by using a visual score system, Ferriman and Gallwey 
(Ferriman.D and Gallwey.J.D 1961,  Yildiz.B.O et al., 2009) that evaluates nine 
body areas, including: the upper lip; chin; chest; upper back; lower back;upper and 
lower abdomen; upper arm and thigh. The areas are assigned a score of 0–4 based on 
the density of terminal hairs. A score of 0 represented the absence of terminal hairs, a 
score of 1 minimally evident terminal hair growth, and a score of 4 extensive terminal 
hair growths. 
3.5. CHRONIC LOW-GRADE INFLMMATION AND OXIDATIVE STRESS 
IN RELATION TO INSULIN RESISTANCE 
Inflammation and oxidative stress have been related to the pathogenesis of PCOS. 
(Zhao.Y et al., 2015, Escobar-Morreale.H.F et al., 2011) 
Oxidative stress, inflammation could induce insulin resistance (IR) mainly via 
interfering with post-insulin receptor signaling pathway, insulin receptor substrate 1-
phosphatidyl inositol 3 kinaseprotein kinase B (IRS1-PI3K-PKB/Akt) pathway. 
(Keane.K.N et al., 2015) 
Chronic low-grade inflammation is considered as an important feature of polycystic 
ovary syndrome (PCOS) and has been suggested to participate in the pathogenesis and 
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development of PCOS.Inflammation has also been demonstrated to be associated with 
IR in PCOS. (        .F et al., 2006) 
It was reported that adipose derived TNF-  levels in mice were increased during the 
advancement of obesity, but when TNF-  was neutralised, insulin sensitivity was 
improved (Hotamisligil.G.S et al., 1993) 
Oxidative stress (OS) and inflammation seem to contribute to hyperandrogenemia in 
PCOS, but detailed interactions still remain unclear, as few investigations have been 
discovered to focus on the subject. In multiinvestigations, OS and inflammation 
markers are discovered to be positively correlated with androgen levels in PCOS 
patients (Yang.Y et al., 2011) 
Oxidative stress has been implicated in the etiology of IR in leukocytes from PCOS 
patients, and an increase in leukocytes has been highlighted as a putative marker of 
low-grade chronic inflammation and early cardiovascular risk in these subjects. 
(Escobar-Morreale.H.F et al., 2011) 
One study found that C - reactive protein (CRP), an inflammatory marker that has 
been shown to predict cardiovascular events in previously healthy women. (Sesso, 
H.D et al., 2003) was significantly higher in women with PCOS and PCO than in 
controls and this difference could not be attributed to age, BMI, waist-to-hip ratio, and 
lipid profile. (Engin-Üstün et al., 2006)   
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3.6. INTERACTIONS BETWEEN GENETIC, METABOLIC, FETAL, AND 
ENVIRONMENTAL FACTORS. 
 PCOS is complex and reflects the interactions between genetic, metabolic, fetal, and 
environmental factors. Among these factors, disordered gonadotropin secretion, 
hyperandrogenemia, insulin resistance and perinsulinemia, ovarian dysfunction, and 
follicular arrest are prominent. Several theories have been proposed to explain the 
pathogenesis of PCOS. One of these is that neuroendocrine defects lead to increased 
pulse frequency and amplitude of LH and relatively low FSH. This causes…..  
Several theories have been proposed to explain the pathogenesis of PCOS. One of 
these is that neuroendocrine defects lead to increased pulse frequency and amplitude 
of LH and relatively low FSH. 
In normal women, the adrenal glands and the ovaries secrete androgens in response to 
ACTH and LH, respectively. (Rosenfield R.L., 1999) Approximately half of the 
androgen production stems from direct secretion and half from enzymes peripherally 
converting 17ketosteroids into androstenedione (predominantly) in skin, liver, and 
adipose tissue. (Bachmann.G et al., 2002) 
The hypothalamicpituitary axis does not directly regulate androgen production in the 
adrenal glands, and intraglandular autocrine and paracrine factors also influence 
androgen production throughout the body. (Ehrman.D.A et al., 1995) 
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A consistent feature of PCOS is disordered gonadotropin secretion with elevated mean 
LH, low or low normal FSH and a persistently rapid frequency of GnRH pulse 
secretion. (Zumoff. B et al., 1983, Kazer.R.R et al., 1987) 
3.6.1. ABNORMAL PITUITARY FUNCTION 
Under normal circumstances, the hypothalamic gonadotropin-releasing hormone 
(GnRH) pulses cause luteneizing hormone (LH) and follicle-stimulating hormone 
(FSH) release. LH stimulates ovarian theca cells to produce androgens (mainly 
androstenedione) and FSH stimulates granulosa cells to convert the androstenedione 
to estrone and estradiol. (McNatty K.P et al., 1979) 
Estrogen and progesterone provide negative feedback to GnRH-secreting neurons as 
well as the pituitary. Adolescents with PCOS have increased LH levels above average 
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follicular phase levels as well as increased pulse secretion. (Blank.S.K et al 2006, 
Taylor.A.E et al., 1997) This pattern is exaggerated in adolescents with increased 
adiposity. (Kasa-Vubu et al., 2010) 
Higher LH levels increase thecal production of androgens, which in turn will 
counteract the LH-suppressive role of female hormones as well as regulation of GnRH 
neurons by progesterone. (Berga.S.L et al., 1993, Eagleson.C.A et al., 2000, 
Turgeon.J.L and Waring D.W 1999) 
Insulin resistance and the consequent development of hyperinsulinemia appear to be 
central in the pathophysiologic mechanism that links PCOS to its concurrent 
metabolic derangements. Compensatory hyperinsulinemia is important in the 
development of metabolic abnormalities and also contribute to the high androgen 
levels observed in women with PCOS. Insulin binds to its cognate receptor on the 
ovarian theca cell, enhancing the luteinizing hormone (LH)-stimulated androgen 
production. (Barbieri.R.L et al., 1986, Nestler.J.E et al., 1991, Nestler.J.E et al., 
1998, Codner.E et al., 2007, Diamanti-Kandarakis.E et al 2008) 
Clinical evidence suggests that elevated insulin levels cause hyperandrogenism, and 
not the other way around, as show n by the decrease in serum androgen levels 
observed when circulating insulin concentrations are lowered by the administration of 
insulin-sensitizing drugs or drugs that inhibit insulin secretion.   
Insulin can also act indirectly to raise the serum concentration of free testosterone, the 
level of which does not seem to be tightly regulated in women, by inhibiting the 
hepatic production of sex-hormone–binding globulin (SHBG). 
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Clinical studies have shown that hyperandrogenism is linked with insulin 
resistance/metabolic syndrome in PCOS women. There are several potential 
mechanisms for the association of androgen excess with insulin resistance, including 
both direct and indirect actions of androgens on insulin target tissues. Studies to define 
the molecular mechanisms whereby androgens interact with insulin effects on glucose 
metabolism in target tissues, as well as the regulation of local androgen production in 
the adipose tissue and its role in metabolism, are required. Exercise training and diet 
efficiently decrease fasting insulin levels and also improve hyperandrogenism by 
increasing SHBG and decreasing androgen levels. Whether in conjunction with 
pharmacotherapy or as a stand-alone treatment, lifestyle modifications (diet and 
exercise training) certainly represent a fundamental strategy for the treatment of 
women with PCOS. 
Figure 1 Flowchart illustrating the relationship between insulin resistance and 
androgens in PCOS. Clinical evidence suggests that elevated insulin levels cause 
hyperandrogenism, and not the other way around, as shown by the decrease in 
serum androgen levels observed when circulating insulin concentrations are lowered 
by the administration of insulin-sensitizing drugs or drugs that inhibit insulin secretion 
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https://www.researchgate.net/publication/26295382_Androgens_in_Polycystic_Ovay_
Syndrome_The_Role_of_Exercise_and_Diet. 
The association between insulin resistance, compensatory hyperinsulinemia and 
hyperandrogenism has provided insight into the pathogenesis of the PCOS. The 
insulin resistance may occur irrespective of BMI, the common association of PCOS 
and obesity has a synergistic deleterious impact on glucose homeostasis and can 
worsen both hyperandrogenism and anovulation. Insulin acts through multiple sites to 
increase endogenous androgen levels. Increased peripheral insulin resistance results in 
a higher serum insulin concentration. 
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Excess insulin binds to the IGF-1 receptors that enhance the theca cells’ androgen 
production in response to LH stimulation. Hyperinsulinemia also decreases the 
synthesis of SHBG by the liver. Therefore, there is an increase in serum free 
testosterone concentration and consequent peripheral androgen action.  
The clinical outcome measures of the study were the improvement in the regularity of 
the menstrual cycle, the BMI and the improvement in the modified Ferriman - 
Gallwey (F-G) score for hirsutism. The biochemical outcome measures will be the 
change in the Serum free testosterone, dehydroepiandrosterone (DHEA), fasting 
insulin level, Glcosylated hemoglobin (HbA1c) and Low Density Lipoproteins (LDL) 
levels. 
Hyperandrogenism is a well established contributor to PCOS aetiology, detected in 
around 60% to 80% of cases. Insulin resistance is a pathophysiological contributor in 
around 50% to 80% of women with PCOS, especially in those with more severe 
PCOS diagnosed on National Institutes of Health (NIH) criteria and in women who 
are overweight. (Legro RS et al., 2004). 
Genetic and environmental contributors to hormonal disturbances combine with other 
factors, including obesity, ovarian dysfunction and hypothalamic pituitary 
abnormalities to contribute to the aetiology of PCOS. Picture .1 (Legro RS et al., 
2002, Doi SA et al., 2005) 
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Picture.1 GENETIC AND ENVIRONMENTAL CONTRIBUTORS  
3.7. OBESITY RELATION WITH INSULIN RESISTANCE 
Considering the baseline defects in insulin sensitivity and secretion in PCOS and the 
deleterious impact of obesity on these measures, women with this condition are 
expected to have a high prevalence of impaired glucose tolerance (IGT, defined by a 
2h post-challenge glucose level 140–200 mg/dl) and Type 2 diabetes. The risk for 
developing glucose intolerance increased with increasing body mass index (BMI); 
the prevalence of IGT and type 2 diabetes were much lower in nonobese women with 
PCOS (10.3% and 1.5%, respectively) compared to the obese and the overall 
population.  
Obese women are more likely to have menstrual irregularity and anvolatory infertility 
than normal-weight women. In reproductive-age women, the relative risk of 
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anovulatory infertility increases at a BMI of 24 kg/m2 and continues to rise with 
increasing BMI. (Rich-Edwards JW et al., 2002) 
The insulin resistance may occur irrespective of BMI, the common association of 
PCOS and obesity has a synergistic deleterious impact on glucose homeostasis and 
can worsen both hyperandrogenism and anovulation. Insulin acts through multiple 
sites to increase endogenous androgen levels. Increased peripheral insulin resistance 
results in a higher serum insulin concentration. Excess insulin binds to the IGF-1 
receptors that enhance the theca cells’ androgen production in response to LH 
stimulation. Hyperinsulinemia also decreases the synthesis of SHBG by the liver. 
Therefore, there is an increase in serum free testosterone concentration and 
consequent peripheral androgen action.  
The clinical outcome measures of the study were the improvement in the regularity of 
the menstrual cycle, the BMI and the improvement in the modified Ferriman-
Gallwey (F-G) score for hirsutism. The biochemical outcome measures will be the 
change in the Serum free testosterone, dehydroepiandrosterone (DHEA), fasting 
insulin level, Glycosylated hemoglobin (Hb A1c) and Low Density Lipoproteins 
(LDL) levels. 
About 42% of patients with polycystic ovary syndrome (PCOS) have the 
complication of obesity. (March, W.A et al., 2009)  
Abdominal obesity is regarded as a common complication of PCOS, and the risk of 
abdominal obesity in PCOS women ranges from 40% to 80% because of the 
differences of people and nations. (Gambineri.A et al., 2001)  
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Body mass index (BMI) is used as a popular criterion in clinic to evaluate obesity; 
however, about 50% of PCOS patients with normal BMI still have abdominal 
obesity. (Kirchengast.S and Huber.J 2001)  
Another study found that IL-18 was higher in lean and obese PCOS participants 
compared to controls matched for BMI and smoking status. (Escobar-Morreale. H.F 
et al., 2004) 
Consistent with a pathophysiologic role for obesity, weight reduction can restore 
regular menstrual cycles in these women PCOS is associated with high rates of 
glucose intolerance resulting from defects in insulin action and β-cell function. 
Obesity substantially exacerbates these defects so obese reproductive-age women 
with PCOS are at very high rates of glucose intolerance. Detection of glucose 
abnormalities in women with PCOS is best performed by means of glucose tolerance 
testing, since fasting glucose levels may be normal despite presence of glucose 
intolerance. In reproductive-age women, the relative risk of anovulatory infertility 
increases at a BMI of 24 kg/m2 and continues to rise with increasing BMI consistent 
with a pathophysiologic role for obesity, weight reduction can restore regular 
menstrual cycles in these women. 
In obesity increased androgen production has been reported especially in women with 
upper-body obesity. This abnormality is further worsened by obesity, especially 
central obesity, since sex hormone binding globulin, or SHBG, levels are reduced in 
this state due to hyperinsulinemia. PCOS is characterized by abnormalities in the 
gonadotropin hormone releasing hormone, or GnRH, pulse generator leading to 
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preferential increase in LH release over follicle stimulating hormone 
(FSH).Independent of BMI, women with PCOS have been reported to have a high 
prevalence of upper-body obesity as demonstrated by increased waist circumference 
and waist-hip ratio compared to BMI-matched control women.  
The Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society 
recommends an assessment of CVD risk factors in women with PCOS and 
assignment of PCOS related CVD risk categories. The “at risk category women with 
PCOS who also display includes obesity (especially abdominal adiposity), cigarette 
smoking, hypertension, dyslipidemia (increased LDL-C and/or non-HDL-C), 
subclinical vascular disease, IGT and a family history of premature CVD (<55 yr of 
age in male relative, < 65 yr of age in female relative). Women with PCOS who also 
meet criteria for the metabolic syndrome, type 2 diabetes mellitus and overt vascular 
or renal disease are considered to be high risk for CVD. (Wild, Carmina, 2010)  
This group recommended that BP, waist circumference and BMI be determined at 
every visit, a lipid profile (total cholesterol, LDL-C, non-HDL-C, HDL-C, and 
triglycerides) be obtained every 2 years and a 2-h post 75-g oral glucose challenge be 
performed with a BMI greater than 30 kg/m2, or alternatively in lean PCOS women 
with advanced age (>40 yr), personal history of gestational diabetes, or family history 
of T2DM. Screening for depression, anxiety and quality of life was also suggested. 
(Dokras, 2011) The recent 3rd PCOS Consensus Workshop Group recommended 
CVD risk assessment at any age is for psychosocial stress, blood pressure, glucose, 
lipid profile (cholesterol, triglycerides, HDL, LDL, and non-HDL cholesterol), waist 
circumference, physical activity, nutrition, and smoking. (Fauser, 2012) 
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The cause of insulin resistance is likewise complex and multifactorial with genetic 
and environmental contributors. Women with PCOS are at increased risk of 
developing IGT and DM2 with prevalence rates of 31.3% and 7.5%, respectively, 
compared to 14% for IGT and 0% for DM2 in age-matched and weight-matched non-
PCOS control women. It is increasingly clear that IGT is also a clinically  relevant 
state where early dentification and intervention improve long-term outcomes. IGT 
has been found to increase the risk of CVD, mortality and progression to DM2 in 
general populations. Recent population based data noted a mortality rate of 5.5% 
over 5 years for those with IGT versus 1.9% with normal glucose tolerance. 
Furthermore, lifestyle intervention, metformin and glitazones can prevent IGT 
progression to DM2, strengthening the argument for early detection of IGT, including 
in high-risk PCOS women. There are currently no generic guidelines for IGT 
screening, only for DM2 based on fasting glucose or more recently on HbA1c as a 
first line. 
MANAGEMENT OF OBESITY IN PCOS  
Weight loss reduces hyperinsulinemia and subsequently hyperandrogenism. In the 
study by Kiddy et al. discussed earlier, about 40% of obese women with PCOS 
(mean body mass index [BMI] ~34 kg/m2) who lost >5% of initial body weight with 
caloric restriction achieved spontaneous pregnancy. (Kiddy DS et al., 1992) 
3.8. GLUCOSE METABOLISM 
Consistent with a pathophysiologic role for obesity, weight reduction can restore 
regular menstrual cycles in these women. PCOS is associated with high rates of 
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glucose intolerance resulting from defects in insulin action and β-cell 
function.Obesity substantially exacerbates these defects so obese reproductive-age 
women with PCOS are at very high rates of glucose intolerance. Detection of glucose 
abnormalities in women with PCOS is best performed by means of glucose tolerance 
testing, since fasting glucose levels may be normal despite presence of glucose 
intolerance.In reproductive-age women, the relative risk of anovulatory infertility 
increases at a BMI of 24 kg/m2 and continues to rise with increasing BMI. Consistent 
with a pathophysiologic role for obesity, weight reduction can restore regular 
menstrual cycles in these women. 
In obesity increased androgen production has been reported especially in women with 
upper-body obesity. This abnormality is further worsened by obesity, especially 
central obesity, since sex hormone binding globulin, or SHBG, levels are reduced in 
this state due to hyperinsulinemia. PCOS is characterized by abnormalities in the 
gonadotropin hormone releasing hormone, or GnRH, pulse generator leading to 
preferential increase in LH release over follicle stimulating hormone 
(FSH).Independent of BMI, women with PCOS have been reported to  have a high 
prevalence of upper-body obesity as demonstrated by increased waist circumference 
and waist-hip ratio compared to BMI-matched control women.  
A substantial proportion of PCOS patients have abnormalities on the oral glucose 
tolerance testing at the time of diagnosis. When assessed overall (obese and lean 
together), PCOS patients had a 31% rate of impaired glucose tolerance and 7.5% met 
the criteria for type 2 diabetes mellitus.(Legro RS et al., 1999) 
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 In those with normal glucose tolerance at baseline 17% had developed impaired 
glucose tolerance or type 2 diabetes mellitus over time, while 54% of those with 
impaired glucose tolerance at baseline had progressed to type 2 diabetes mellitus. 
Further support for the high prevalence of abnormal glucose tolerance in PCOS is the 
10-fold increased risk of developing gestational diabetes mellitus compared to the 
general population (baseline risk ~3%). (Glueck CJ et al., 2002) 
Lastly, Cibula et al. noted a 4-fold increased prevalence of type 2 diabetes mellitus in 
women with PCOS who had undergone ovarian wedge resection for polycystic 
ovaries some 20 to 40 years earlier compared to a closely matched control 
population. (Cibula D et al., 2000) 
PCOS was associated with an increase in glucose abnormalities, suggesting that 
obese PCOS adolescent are at increased risk for developing glucose intolerance 
(IGT) and T2DM compared with their non-PCOS counterparts. (Harwood K et al., 
2007, Rossi.B et al., 2008)  
The prevalence of IGT (fasting blood glucose levels of 100–125 mg/dl, and/or 2 h 
postprandial glucose level after a 75 g oral glucose challenge between 140–200 
mg/dl) is not clear. Bridger et al., showed that in a study of 22 obese adolescents with 
PCOS, only one participant had IGT (4.5%). (Bridger.T et al., 2006) 
Others studies involving obese adolescents with PCOS report rates of IGT as high as 
(Palmert M.R et al., 2002) to 52%. (Arslanian S.A et al., 2001) 
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By contrast, nonobese adolescents with evidence of PCOS or ovarian 
hyperandrogenism do not seem to have an increased risk of IGT as shown in studies 
carried out. (Ibanez et al., 2000, Silfen M.E et al., 2003) 
 As adults, the most reliable screening test for IGT in PCOS adolescents is the 2-hr 
OGTT after a 75-g glucose load interpreted using ADA guidelines. (Salley, K.E et 
al., 2007) 
This is an interesting paper that reviews ADA guidelines. Although the most 
appropriate screening interval is not clearly defined, the conversion from IGT to 
T2DM can occur in as little as 5years most likely because of the strong correlation of 
PCOS and insulin resistance and β-cell failure. (Saad.R et al., 2005) 
3.9.   CARDIOVASCULAR RISK FACTORS 
Cardiovascular Risk Factors and Disease in PCOS studies have shown either a 
greater prevalence of diagnosed hypertension or higher ambulatory blood pressure in 
PCOS. The pattern of dyslipidemia in PCOS is in keeping with IR, increased 
triglycerides, and low HDL-cholesterol. (Wild RA et al., 1985, Wild RA et al., 
1992, Slowinska-Srzednicka J et al., 1991, Talbott E et al., 1995) 
Dyslipidemia The prevalence of at least one abnormal lipid level by National 
Cholesterol Education Program guidelines approaches 70%.  (Legro, R.S et al., 
2001) in adolescents, PCOS. (Demirel.F et al., 2007) 
Women with PCOS may also have higher levels of small, dense LDL-cholesterol 
(Pirwany.IR et al., 2001), homocysteine (Loverro G et al., 2002), plasminogen 
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activator inhibitor type 1 (Velazquez EM et al, 1997), decreased insulin induced 
vascular relaxation (Kelly CJ et al 2002) and endothelial dysfunction. (Paradisi G et 
al., 2000) As an extension of these data on risk factors, two retrospective studies of 
patients undergoing coronary angiography found women with a significant history of 
hirsutism to be more likely to have coronary artery disease. (Wild.RA et al., 1990, 
Birdsall.MA et al., 1997) 
The Nurses' Health Study cohort revealed that women with “usually irregular” or 
“very irregular” menstrual cycles had an increased risk of coronary artery disease 
events of approximately 20% and 60%, respectively versus those with “very regular” 
cycles. (Solomon.CG et al., 2002) Cibula et al. reported a 4-fold increased risk of 
coronary artery disease in PCOS patients followed 20 to 40 years. 
The cause of insulin resistance is likewise complex and multifactorial with genetic 
and environmental contributors. Women with PCOS are at increased risk of 
developing IGT and DM2 with prevalence rates of 31.3% and 7.5%, respectively, 
compared to 14% for IGT and 0% for DM2 in age-matched and weight-matched non-
PCOS control women. It is increasingly clear that IGT is also a clinically relevant 
state where early identification and intervention improve long-term outcomes. IGT 
has been found to increase the risk of CVD, mortality and progression to DM2 in 
general populations. Recent population based data noted a mortality rate of 5.5% 
over 5 years for those with IGT versus 1.9% with normal glucose tolerance. 
Furthermore, lifestyle intervention, metformin and glitazones can prevent IGT 
progression to DM2, strengthening the argument for early detection of IGT, including 
in high-risk PCOS women. There are currently no generic guidelines for IGT 
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screening, only for DM2 based on fasting glucose or more recently on HbA1c as a 
first line. 
Alongside insulin resistance, metabolic syndrome, IGT and DM2, women with PCOS 
also have increased novel cardiovascular risk factors (inflammation, oxidative stress 
and impaired fibrinolysis).Given that large longitudinal cohort studies have reported 
up to 65% of CVD deaths occur in subjects with impaired glucose metabolism and 
that IGT and DM2 are increased in PCOS, it would be expected that women with 
PCOS would have increased CVD risk. 
Addressing hyperandrogenism is clinically important and monitoring for and 
managing longer-term metabolic complications, including dyslipidaemia, IGT, DM2, 
and cardiovascular risk factors, is crucial. Consideration should be given to screening 
high-risk family members for metabolic abnormalities also. Overall, further research 
is needed in this complex condition. In the interim, comprehensive evidence-based 
guidelines are needed to guide consumers and clinicians in optimal PCOS 
management. 
CARDIO METABOLIC ASPECTS OF POLYCYSTIC OVARIAN 
SYNDROME 
The prevalence of obesity in PCOS varies widely, between approximately 10–
50%.Obese PCOS have lower levels of luteinizing hormone (LH), sex hormone 
bindingglobulin (SHBG), dehydroepiandrosterone (DHEAS), dihydrotestosterone, 
free insulin-like growth Factor (IGF)-I, high-density lipoprotein, and higher low-
density lipoprotein, compared with the nonobese PCOS group. 
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3.10. BLOOD PRESSURE IN PCOS 
Etiology of hypertension that occurs in the setting of PCOS is also multifactorial, 
including factors such as hyperandrogenemia, insulin resistance, obesity, and 
increased sympathetic nervous system activity. 
Androgen Excess - There are data demonstrating that the hyperandrogenemia in 
PCOS women is associated with systolic and diastolic blood pressures in women 
with PCOS, independent of obesity or insulin resistance. (Chen.M.J et al., 2007)  
Androgen excess has also been associated with an increase in cIMT in women with 
PCOS. (Luque-Ramírez.M et al., 2007) Increased cIMT has been widely used as a 
reflection of preclinical atherosclerotic disease, a contributor to the development of 
hypertension. 
Hypertension may be secondary to enhanced sodium retention occurring in the 
setting of hyperinsulinemia. High insulin levels have been associated with a 
subsequent increase in intracellular sodium and calcium. (Resnick.L.M. 1992) 
Obesity is a well-established risk factor for hypertension and it has been considered 
the primary etiology implicated in the increased blood pressure in women with 
PCOS.       -       .M et al., 2007) 
Greater sympathetic nerve activity was found in a study of 20 women with PCOS 
who were compared to 18 weights and age-matched control women. 
(Sverrisdottir.Y.B et al., 2008)  
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The sympathetic nerve activity to the muscle vascular bed among women with PCOS 
was increased and highly correlated with testosterone level and to a lesser degree the 
cholesterol level. In addition, androgen excess as well as insulin resistance 
(Muniyappa.R et al., 2007) and obesity. (Müller-Wieland.D et al., 1998) have been 
implicated in stimulating the autonomic nervous system, thereby, each serving as a 
potential mediator of the hypertension observed in PCOS. 
Hypertension is a significant contributor to the risk for cardiovascular disease. The 
increased prevalence of hypertension in women with PCOS may contribute to the 
increased risk of cardiovascular disease in women with PCOS. Thus, the Androgen 
Excess and Polycystic Ovarian Societies recommend that blood pressure be obtained 
in women with PCOS at every visit and that prehypertension be detected and treated 
given the potential benefit of lowering blood pressure for the prevention of CVD. 
(Wild.R.A et al., 2010) 
In the Nurses’ Health Study, a history of menstrual cycle irregularity was associated 
with an increased risk of non-fatal and fatal coronary heart disease. (Solomon et al., 
2002) This might be explained by a high rate of PCOS with its associated metabolic 
disturbances in these women, although no other clinical or biochemical androgen 
data was available to confirm that menstrual irregularity was due to PCOS. 
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 3.10. PREVALENCE OF PCOS 
Prevalence of polycystic ovary syndrome in young women from North India: A 
Community based study 
The prevalence reported in earlier studies varies between 2.2% to 26%. These 
variations are due to difficulties in hormonal evaluation and lack of consensus on 
diagnostic criteria. Insulin resistance is central to the pathogenesis of PCOS, and 
Indians are known to have high prevalence of insulin resistance, so the prevalence of 
PCOS may be high in our population. Prevalence of PCOS in young women (18-25 
years) was 3.7%, and majority of them were lean. Even at this young age, these 
women were at a high risk of metabolic syndrome because of the increased 
prevalence of abnormal waist hip ratio and prehypertension. (Knochenhauer.E.S et 
al., 1998, Azziz.Ret al., 2004, Diamanti-Kandarakis.E et al., 1999, March.W.A et 
al., 2009) 
Metabolic syndrome is another cluster of endocrine disturbances, including insulin 
resistance, dyslipidemia, obesity, and hypertension. (Ma.Y.M et al., 2010)  
It is associated with a two-fold increased risk of cardiovascular disease and a five-
fold increased risk of type 2 diabetes. (Kumarapeli.V et al., 2008)This illustrates the 
importance of early detection of insulin resistance and metabolic syndrome with 
subsequent application of preventive measures in women with polycystic ovary 
syndrome. 
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3.11. PHARMACOLOGICAL INTERVENTIONS    -      
INSULIN SENSITIZERS 
Metformin is effective in the treatment of metabolic syndrome and modestly 
increases menstrual regularity and ovulation, and may improve hirsutism in patients 
with PCOS. (Harborne et al., 2003) 
Metformin treatment in lean women with PCOS also improves insulin resistance and 
hyperandrogenism without a change in BMI. (Nestler and Jakubowicz 1997) Whilst 
metformin appears to induce cardio-protective effects on serum insulin (Sahin et al 
2004), serum lipids (Ibanez et al 2004), and PAI-1 (Song et al 2002), the actual 
protection from long-term mortality and morbidity of cardiovascular disease has yet 
to be demonstrated. In addition, it has been suggested that metformin has a beneficial 
effect on endothelial function in patients with polycystic ovarian syndrome. (Orio et 
al., 2005) 
3.12   YOGANIDRA INTERVENTIONS FOR PCOS 
The characteristic feature of YogaNidra was the systematic rotation of consciousness 
in the body, which originated from the tantric practice of Nyasa (meaning to place or 
to take the mind to that point).Nyasa, was practiced in a sitting posture and involved 
the use of specific mantras which were placed, felt or experienced at different parts of 
the body. First the name of the part was recited, then it was visualized or touched, 
and the mantra was placed there. Nyasa was a means of concentrating the physical 
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body by instilling higher awareness or divine consciousness into the various parts 
during tantric ritual practice. 
In YogaNidra perhaps the most effective means of training the mind is found in 
Sankalpa, which you make for yourself during each practice. Anything in life can fail 
you, but not the Sankalpa made during YogaNidra. Sankalpa is an important stage of 
YogaNidra and a powerful method of reshaping your personality and direction in life 
along positive lines. 
The Sankalpa takes the form of a short mental statement which is impressed on the 
subconscious mind when it is receptive and sensitive to autosuggestion during 
YogaNidra. 
 During anxiety, there is an increased response of hypothalamus and heightened 
sympathetic activity. YogaNidra appears to regulate hypothalamus, in a way resulting 
in decreased sympathetic (excitatory) nervous activity and increased parasympathetic 
(inhibitory) function. (Satyananda S. YogaNidra 2009) 
Khushbu Rani et al., 2016 found significant decrease in their degree of depressive 
symptoms (according to the psycho-biological general wellbeing Index).There was 
significant change in TSH, FSH, LH, and Prolactin levels in intervention group as 
compared to the control group.  
Previous studies found that long term practice of yoga lead to decreased TSH, growth 
hormone, and prolactin imbalances significantly. Metabolic effects of meditation 
(YogaNidra) includes a decreased adrenocortical activity, long term decreased 
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cortisol secretion and lesser thyroid stimulating hormone (TSH) abnormalities. 
(Schell FJ et al., 1994) 
Metabolic effects of meditation (YogaNidra) includes a decreased adrenocortical 
activity, long term decreased cortisol secretion and decreased thyroid stimulating 
hormone (TSH). Imbalances in the hormonal profile also predispose women to 
depression, especially in relation to pituitary, thyroid and reproductive hormones.  
The practice of hatha yoga and asanas has been found to be extremely effective in 
rectifying the situation. (Muktananda S Nawa Yogini Tantra. 2004) 
Menstruation is dependent on the proper functioning of the chain made up of 
hypothalamus- pituitary-ovary and uterus. Pituitary hormones, follicle stimulating 
hormone (FSH), luteinizing hormones (LH), prolactin and thyroid hormones are 
required for normal development of ova and need to be investigated in cases of 
chronic anovulation, oligomenorhea and amenorrhea. (Lobo RA 1999) 
 It was inferred that after YogaNidra practice, patients acquired relief in heavy 
bleeding and irregular menstrual periods. As other research project, our study has 
some limitations. 
The main limitation was that amenorrhea, dysmenorrhea, oligomenorrhea, polymen-
orrhea, menorrhagia, metrorrhagia, and hypo menorrhea were included in the study 
all together. The sample size was not large enough to analyze the hypomenorrhic 
group and hypermenorrhic subgroups separately. The information of the menstrual 
cycle was based on the participant’s self-reports not based on ultrasound scans; this is 
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also another limitation of the study. In future this study could be repeated in other 
populations with large number of patients. Further, some other yogic practices may 
be tried and compared with the present ones. 
YogaNidra can be an effective practice to overcome the psychiatric morbidity 
associated with menstrual irregularities apart from bringing the hormonal profile 
towards normalcy. Therefore, Yogic relaxation training (YogaNidra) could be 
prescribed as an adjunct to conventional drug therapy for menstrual dysfunction. 
(Yadav et al., 2016) 
YogaNidra is an effective technique, for physical or mental relaxation. Qualitatively 
YogaNidra is different from relaxation. It is a ‘sleep’ where all our burdens are 
removed in order to attain a more blissful state of awareness. Difference between 
YogaNidra and an ordinary sleep lies in intensity of a relaxation which is much more 
intense in YogaNidra than in ordinary sleep. Aim of YogaNidra is to focus the mind 
to achieve relaxation and increase Wellness. We used the YogaNidra technique, as 
mentioned in book YogaNidra by Swami Satyananda Saraswati. The final yoga 
classes conducted for 35 min per day, seven days a week for last two weeks. 
Amita S et al., 2009 suggest that subjects on Yoga-nidra with drug regimen had 
better control in their fluctuating blood glucose and symptoms associated with 
diabetes, compared to those were on oral hypoglycaemics alone. 
South East Asian countries have a highest burden of diabetes. In India the prevalence 
of diabetes is rising rapidly especially in the urban population because of increasing 
obesity and reduced physical activity. An objective of this study is to evaluate the 
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effect of Yoga-Nidra on blood glucose level in diabetic patients. (Amita S et al., 
2009) 
KhushbuRani et al.,2011 found significant improvement in pain symptoms 
(P<0.006), gastrointestinal symptoms (P<0.04), cardiovascular symptoms (P<0.02) 
and urogenital symptoms (P<0.005) after 6 months of YogaNidra therapy in 
Intervention group in comparison to control group, the results indicate that 
somatoform symptoms in patients with menstrual disorder can be decreased by 
learning and applying a program based on Yogic intervention 
(YogaNidra).YogaNidra appears to be a promising intervention for psychosomatic 
problems. It is cost-effective and easy to implement.  
A randomized controlled trial  observe the effect of YogaNidra practice on hormone 
levels in patients who had menstrual irregularities.YogaNidra practice was helpful in 
patientswith hormone imbalances, such as dysmenorrhea, oligomenorrhea, 
menorrhagia, metrorrhagia, and hypomenorrhea. (Rani M et al., 2011) 
A significant positive effect was observed when yoga therapy was used as an adjunct 
in the patients of menstrual disturbances. There were significant improvements in the 
blood pressure, postural hypotension and sustained hand grip, heart rate expiration 
inspiration ratio and 30:15 beat ratios of the subjects after yogic practice. (Monika et 
al., 2010)  
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YogaNidra – Deep Relaxation 
Deep relaxation may have substantial benefits on physical and psychological health. 
The relaxation response, a physiological phenomenon considered to be the opposite 
of the fight-or flight stress response, is of increasing interest in the medical field as a 
preventative and alternative treatment for stress-related disorders. Methods of 
inducing the relaxation response include some forms of yoga or meditation, 
progressive muscle relaxation, and stress management training. (Rainforth et al., 
2008) The Relaxation Response Resiliency Program (3RP) is a standardized, 8-week 
program incorporating a variety of modalities to increase relaxation and resiliency. In 
a recent study, Stahl and colleagues (2015) found that a year-long intervention 
incorporating these various methods to increase the relaxation response, including 
yoga and meditation, decreased billable medical encounters by 43 percent. In 
addition to stress, researchers have suggested that relaxation may have positive 
effects on cardiovascular health (Dusek et al., 2008), chronic pain (Caudill et al., 
1991), and menopausal symptoms. (Irvin et al., 1996) 
The focus of the literature on the relaxation response is largely medical. However, 
relaxation has also been suggested as a potential preventative measure for burnout-
related stress based on the ancient Tantric practice of nyasa, in which a mantra is 
repeated mentally at with concentration at specific parts of the body (Saraswati, 
1976). The yogic texts describe a state of consciousness called turiya, or the fourth 
state, which is a state of consciousness beyond waking, sleeping, and dreaming 
(Saraswati, 1976, Birch & Hargraves 2015). This state is considered to lead to 
Samadhi, or bliss.Researchers have reported significant decreased in rage, anxiety, 
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and emotional reactivity (Stankovic, 2011), increased joy and ability to manage 
stress, and increased sleep. (Pence et al., 2014) 
YogaNidra may have positive effects in medical patients. Two studies have looked at 
the effect of YogaNidra on psychological and physiological symptoms associated 
with menstrual disorders and found significant positive results (Rani et al., 2012, 
Singh et al., 2012).  
A study by (Pritchard et al., 2009) examined the effects of YogaNidra on perceived 
stress levels in medical patients with cancer and multiple sclerosis and found the 
perceived stress was significantly reduced in the 12 participants after the 6-week 
program. 
In a study by Eastman-Mueller et al., 2013, a sample of sixty-six college students 
participated in an 8-week YogaNidra intervention. Researchers assessed changes in 
worry and perceived stress. The data suggests that the intervention was helpful in 
reducing students’ worry and stress. 
There is evidence to suggest that yoga, meditation, and relaxation have positive 
effects on Participants were asked to complete a baseline assessment using the 
Perceived Stress Scale (PSS-10; Cohen et al., 1983). The PSS-10 is a widely used 
10-item scale used to measure the degree to which events in one’s life have been 
stressful, overwhelming, and unpredictable in the past month on a 0-4 Likert scale. It 
measures the perceived experience of stress, rather than objective variables that may 
contribute to increased stress. Participants were not asked about events in their life 
which may have contributed to stress, but rather the perceived experience of stress in 
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the last month. The PSS has been measured and tested effectively for reliability and 
validity. (Cohen et al., 1983) 
The brain is the physical mediator of consciousness, linking mind, body and 
emotions into one harmonious unit. The neurosurgeon affects the body by stimulating 
the brain. The practitioner of YogaNidra begins at the other end of the nerve pathway 
by heightening the awareness of the body in order to stimulate the brain .The 
progressive movement of awareness through the parts of the body not only induces 
physical relaxation, but clears all the nerve pathways to the brain, but those 
governing the physical activity and those concerned with incoming information. 
In addition to improving mood and decreasing stress, YogaNidra as a stress 
management intervention, appear in other populations to be capable of normalizing 
HPA axis regulation as well as lowering SNS activity. YogaNidra directed at better 
managing stress may be used to address the cortisol secretion abnormalities often 
present in PCOS women, especially since standard treatment with metformin does 
not appear to affect physiological responses to stress. If so, stress management 
approaches may also have the secondary effects of reducing hyperandrogenism, as 
has been demonstrated in women with other conditions. Much more research 
investigating the effectiveness of YogaNidra interventions among this population is 
needed, but this small study provides some evidence that these approaches are 
promising. Among the general population, interventions have helped individuals 
achieve changes such as reductions in BMI, percent fat, waist circumference, lipids, 
and caloric intake.  
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4. METHODOLOGY 
MATERIALS AND METHODS 
Study design         :     Experimental pre post study 
Study population:  
40 PCOS women of age group between 18 -35 years, who attend the Government 
Yoga & Naturopathy Medical College Hospital outpatient department, Arumbakkam, 
Chennai -106, will participate in the study. (The diagnosis of PCOS was based on the 
Rotterdam criteria 2003 and inclusion criteria of this study). 
After explaining the purpose of this study & obtaining informed written consent, a 
detailed case history and clinical Examination will be performed to the patients.  
Ethical committee clearance:  
Clearance from the Institutional ethical committee was obtained prior to the 
conduction of the study. 
Informed consent:  
 Informed consent from the participants was obtained after explaining the protocol 
and benefits to them.   
Selection of the subjects: 
Inclusion Criteria 
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1. Those who satisfied the Rotterdam Criterion for PCOS will be included in the 
study. 
2. Women with PCOS under any treatment.   
3. Those who satisfied the Cohen-perceived stress scoring. 
Exclusion Criteria 
1. Pregnancy 
2. Woman who were using oral contraceptives / hormone treatment/insulin-
sensitizing agents/ ovulation induction agents within previous 6 months. 
3. Woman who were practicing yoga from a month or more. 
4. Thyroid dysfunctions 
5. Conditions that mimic PCOS like ovarian hyperthecosis, congenital adrenal 
hyperplasia, and Idiopathic hirsutism 
6. Subjects with neoplastic, hepatic, respiratory and any cardiovascular disorder or 
other medical illness (i.e. respiratory and heart failure and renal disease) 
Data collection and Analysis:  
1. Anthropometric Measurements - Height, Weight, BMI, Waist-Hip Measurement 
and ratio 
2. Blood Glucose     -   OGTT, HBA1C, FBS, PPBS 
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3. Lipid Profile       -   TOTAL CHOLESTEROL, LDL, HDL, TGL 
 Analysis Plan        :     Paired Student‘t’ test, R statistical free software      
             version 3.2.0  
Study questionnaire: 
Cohen-perceived stress scoring. 
Modified Ferriman - Gallwey scoring system (Ferriman D and Gallwey J 1961) 
History of reproductive illnesses was obtained by using CRF. 
Measurement of the anthropometric indices: 
Standing height: Measuring tape was used to measure the standing height in 
centimeters. 
Weight: Weight as recorded in kilograms using the portable weighing machine. 
Body Mass Index: BMI was calculated by using the formula. 
BMI= weight (in kg)/ht in meter
2  
            (Quetelet index) 
Anthropometric measurements included a waist circumference in centimeters 
measured at the narrowest circumference, midway between the upper border of iliac 
crest and the lower rib margin, whereas the hip circumference was taken as the 
widest measurement at the level of the greater trochanter with subject was standing 
and breathing normally. (To rule out abdominal type obesity, which are 
characteristics for PCOS women)  
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Height was recorded in centimeters and weight in kilograms.  
Body mass index (BMI) was calculated as weight in kilograms divided by the square 
of height in meters (kg/m). Overweight was defined as a BMI between 25.0 and 29.9, 
and obese as 30.0 or higher according to World Health Organization categories. 
HIRSUTISM 
Clinical hyperandrogenism 
Hirsutism was assessed by Ferriman Gallwey score of ≥8 over 9 body parts. 
Hirsutism is evaluated using a modified Ferriman–Gallwey scoring system. 
(Ferriman D and Gallwey J 1961)  This tool is used to evaluate hair growth at seven 
sites: upper lip, chin/face, chest, back, abdomen, arms, and thighs. A score of 0 is 
given in the absence of terminal hair growth and a score of 4 is given for extensive 
growth.A total score of 8 or more is indicative of hirsutism. (Unluhizarci K et al., 
2012) criteria 
ROTTERDAM CRITERIA 
The diagnosis was based on the 2003 Rotterdam consensus (the Rotterdam European 
Society for Human Reproduction and Embryology (EHSRE)/American Society for 
Reproductive Medicine (ASRM) – sponsored PCOS consensus workshop group) 
with at least two of the following features:  
(i) oligo-ovulation or chronic anovulation, amenorrhea 
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Oligo-ovulation and/or anovulation was characterized by oligomenorrhea 
(intermenstrual intervals of ≥35 days) and amenorrhea (intervals >3 months). 
(ii) Clinical and/or biochemical hyperandrogenism, and  
(iii) Ultrasound appearance of polycystic ovaries.  
A standard questionnaire was used to document length of menstrual cycles; personal, 
medical, and family history of diabetes; hypertension; obesity;  
and ischemic heart disease. Signs of androgen excess (hirsutism, acne, and alopecia) 
and insulin resistance were noted in the physical examination. 
BLOOD PRESSURE CHECK UP 
 Sitting blood pressure was measured after a 5-min rest using a standard 
sphygmomanometer. 
BIOCHEMICAL INVESTIGATION  
Overnight fasting blood sample and a 75 g oral glucose tolerance test was obtained in 
all women. Impaired fasting glucose, impaired glucose tolerance test, and diabetes 
were defined in accordance with the American Diabetes Association revised 
definition. 
 After 10-12 hours of overnight fasting, blood sample (5 ml) will be taken for 
OGTT     - Glucose oxidase peroxidase method 
HbA1C   - HPLC 
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FBS, PPBS 
LIPID PROFILE 
Total cholesterol - Cholesteroloxidase peroxidase method (Photometry, Enzymatic) 
HDL Direct - Polyethylene Glycol precipitation method 
LDL Direct - Poly vinyl sulfonic acid (precipitation method) 
TGL - Glycerol phosphate oxidase method 
The samples were stored at -20 ° C until it is used for estimating the Blood glucose 
and Lipid profile.  
The 40 PCOS individuals selected and did YogaNidra for 40 minutes over a period of 
3 months. At the end of 12 weeks, re-estimation of Blood glucose, Lipid profile, 
Blood pressure and re-evaluation BMI and Waist hip ratio was done. 
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5. RESULTS 
Table.4: Anthropometric parameters of the study participants 
 
 
 
 
 
 
 
Table.1 showed the anthropometric parameters of the study  
participants. Mean average of the subject was 26.13 yrs with 
 height of 155.6 cm and weight about 74.59 kg. The Mean BMI was 
 30.75 kg/m
2
. 
 
 
 
 
Variables Mean±SD 
Age 26.13±5.30 
Height 155.6±4.17 
Weight 74.59±12.97 
BMI 30.75±4.75 
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Table.5: Effect of YogaNidra practice on  
Resting Cardiovascular parameters 
Variables Before After P value 
Weight 74.59±12.97 70.25±12.14 0.001 
BMI 30.75±4.75 28.92±4.44 0.001 
Waist hip ratio 0.84±0.03 0.80±0.02 0.02 
SBP 128.70±8.46 122.0±9.26 0.0001 
DBP 78.42±6.42 72.0±8.72 0.0001 
         SBP - Systolic blood pressure, 
           DBP - Diastolic blood pressure, 
BMI - Body mass index. 
After YogaNidra Heart rate, SBP and DBP reduced significantly 
(P<0.001) after yoga nidra showed the parasympathetic 
domination over sympathetic nervous system. 
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Table.6: Effect of YogaNidra practice on 
Blood Glucose in PCOS subjects 
 Before After P value 
FBS 90.70±13.54 83.08±10.97 0.001 
PPBS 129.5±14.23 113.3±13.25 0.001 
HbA1C 5.68±0.68 5.06±0.42 0.0001 
Data Expressed Mean±SD. 
After YogaNidra, there was a significant (P <0.001) improvement  
was in the subjects especially 
 FBS from 90.70±13.54 to 3.08±10.97 
PPBS from 129.5±14.23 to 113.3±13.25 
 HbA1C (5.68±0.68vs5.06±0.42) 
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Table.7: Effect of YogaNidra practice on 
GTT in PCOS subjects 
 Before After P value 
GTT1 145.0±14.07 127.5±25.25 0.0001 
GTT2 147.2±27.68 135.8±23.60 0.0001 
GTT3 135.3±25.33 125.3±22.53 0.0001 
GTT4 124.6±17.81 112.6±16.83 0.0001 
Data Expressed Mean±SD. 
After YogaNidra, there was a significant (P <0.0001) improvement was in  
the subjects especially  
GTT1 from 45.0±14.07 to 127.5±25.25. 
GTT2 from 147.2±27.68 to 135.8±23.60  
GTT3 from 135.3±25.33 to 125.3±22.53  
GTT4 from 124.6±17.81 to 12.6±16.83 
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Table.8: Effect of YogaNidra practice on Lipid profile in PCOS subjects 
 
 Before After P value 
Cholestrol 177.7±32.61 165.8±32.08 0.001 
Triglycerides 132.9±30.44 118.2±22.09 0.001 
Data Expressed Mean±SD. 
 
After YogaNidra, there was a significant (P <0.001) reduction was  
There among the lipid profile variables in the subjects as below, 
Cholestrol from 177.7±32.61 to 165.8±32.08  
Triglycerides from 132.9±30.44 to 118.2±22.09  
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Table.9: Effect of YogaNidra practice on Lipid profile in PCOS subjects 
 Before After P value 
HDL 39.23±7.27 43.55±6.61 0.0001 
LDL 119.1±29.11 101.1±30.56 0.0001 
VLDL 26.70±6.25 28.65±5.61 0.0001 
 
After YogaNidra, there was a significant (P <0.0001) reduction was 
there among the lipid profile variables in the subjects as below 
LDL from 119.1±29.11 to 101.1±30.56 
VLDL from 26.70±6.25 to 28.65±5.61 
HDL from 39.23±7.27 to 43.55±6.61 
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6. DISCUSSION 
In this study   after YogaNidra, there was a significant (P <0.001) reduction was 
seen in the subjects especially FBS from 90.70±13.54 to 3.08±10.97, PPBS from 
129.5±14.23 to 113.3±13.2, HbA1C (5.68±0.68vs5.06±0.42) and there was a 
significant (P <0.0001) reduction was in the subjects especially GTT1 from 
45.0±14.07 to 127.5±25.25 GTT2 from 147.2±27.68 to 135.8±23.60 GTT3 from 
135.3±25.33 to 125.3±22.53 GTT4 from 124.6±17.81 to 12.6±16.83 
In this study after YogaNidra heart rate, SBP and DBP reduced significantly 
(P<0.001) showed the parasympathetic domination over sympathetic nervous 
system. 
In this study   there was a significant (P <0.001) reduction in the subjects among 
the lipid profile variables Cholestrol from 177.7±32.61 to 165.8±32.08, 
Triglycerides from 132.9±30.44 to 118.2±22.09 and also significant (P <0.0001) 
reduction among the lipid profile variables LDL from 119.1±29.11 to 101.1±30.56, 
VLDL from 26.70±6.25 to 28.65±5.61, HDL from 39.23±7.27 to 43.55±6.61 in the 
subjects.In this YogaNidra intervention, there was a significant (P <0.0001) 
reduction among the Anthropometric parameters in the subjects, weight from 
74.59±12.97to 70.25±12.1, BMI from 30.75±4.75 to 28.92±4, waist hip ratio from 
0.84±0.03 to 0.80±0.02 
PCOS Women  possible  to show evidence of  exaggerated SNS and defect in 
HPA-axis, signifying that YogaNidra  will improve the coping up of stress , 
positive attitude including stress management interventions  to regulate the HPA 
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axis (Antoni MH et al., 2000, Cruess DG et al., 2000, Phillips K et al.,2008 )   as 
well as lowering SNS activity (Antoni MH et al .,2001) 
Techniques  like  relaxation  and cognitive behavioral therapy will reduce stress 
may be used to address the cortisol secretion abnormalities often present in PCOS 
women, especially metformin does not appear to affect physiological responses to 
stress. (Benson S et al., 2009) Stress management intervention might have the 
secondary effects of reducing hyperandrogenism that is demonstrated in women 
with other conditions (Cruess D et al., 2001) 
Very little research has employed cognitive behavioral therapy (CBT) or other 
psychological interventions among women with PCOS. The only such study 
published to date is a pilot study conducted among adolescents with PCOS (Rofey 
DL et al., 2009) 
8-week CBT intervention resulted in significant decreases in weight and depressive 
symptoms and significant improvements in menstrual regularity and sleep-related 
breathing. This study shows some evidence that these approaches are 
promising.Among the general population; CBT interventions have helped 
individuals to achieve reductions in BMI, percent fat, waist circumference, lipids, 
and caloric intake. (Mefferd K et al., 2007, Vignolo M et al., 2008, Ash S et al., 
2006) 
Significant improvement in anxiety scores after Yoga Nidra intervention following 
meditation. (Eppley KR et al., 1989) and breathing exercises (Brown RP and 
Gerbarg PL 2005) In anxiety state, increased response of hypothalamus and 
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increased sympathetic activity. YogaNidra appears to regulate hypothalamus, in a 
way resulting in decreased sympathetic (excitatory) nervous activity and increased 
parasympathetic (inhibitory) function.  (Satyananda SS. Yoga nidra. 2009) 
YogaNidra intervention gave a significant decrease in depressive symptoms 
(according to the psycho-biological general wellbeing Index).Previous studies have 
also shown that using yoga interventions inother conditions (cancer survivors, self-
reported emotional distress), found to be effective in depressive and mood 
symptoms, as well as anxiety and physical well-being. (Michalsen A et al., 2005) 
Significant improvement in positive wellbeing, general health and vitality in 
intervention group. YogaNidra is believed to balance psychic and vital energies 
within the psychic channels (Nadis) of the energy framework underlying the 
physical body. 
Free flow of these energies is considered to be the basis of optimal physical and 
mental health. Findings from other studies also are in line with present study. 
(Basavaraaddi IV et al., 2008, Kiecolt-Glaser Jket al., 1992, Strijk JE et al., 
2009) 
Previous studies have found significant improvement in self-esteem with Yogic 
exercises. (Benavides S et al., 2008) 
YogaNidra intervention program decreased depressed mood, feelings of guilt, 
insomnia, genital problems, tension, fear and anxious mood which are symptoms 
included as items of PGWBI. Tsunami survivors of the Andaman Islands was  a 
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significant decrease in self rated fear, anxiety, sadness and disturbed sleep, 
respiratory and heart rate was also significantly improved.( Telles  S  et al.,2007) 
Significant change in TSH, FSH, LH, and Prolactin levels, also metabolic effects of 
meditation (Yoga Nidra) includes a decreased adrenocortical activity, long term 
decreased cortisol secretion and lesser thyroid stimulating hormone (TSH) 
abnormalities. (Schell FJ et al., 1994) 
Metabolic effects of meditation (Yoga Nidra) includes a decreased adrenocortical 
activity, long term decreased cortisol secretion and decreased thyroid stimulating 
hormone (TSH). Imbalances in the hormonal profile also predispose women to 
depression, especially in relation to pituitary, thyroid and reproductive hormones. 
(Muktananda S. Nawa Yogini Tantra   2004) 
Menstruation is dependent on the proper functioning of the chain made up of 
hypothalamus- pituitary-ovary and uterus.Pituitary hormones, follicle stimulating 
hormone (FSH), luteinizing hormones (LH), prolactin and thyroid hormones are 
required for normal development of ova and need to be investigated in cases of 
chronic anovulation oligomenorhea and amenorrhea, after Yoga Nidra practice, 
patients acquired relief in heavy bleeding and irregular menstrual periods. 
Imbalances in the hormonal profile also predispose women to depression, 
especially in relation to pituitary, thyroid and reproductive hormones. 
Yoga Nidra is believed to balance psychic and vital energies within the psychic 
channels (Nadis) of the energy framework underlying the physical body. The 
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practice of hatha Yoga Nidra has been found to be extremely effective in rectifying 
the situation. 
Depending on the symptom, patient seeks treatment.Clomiphene has shown the 
best results in treating infertility, whereas data are limited regarding the 
pharmacological treatment of androgenic symptoms. Long-term consequences of 
PCOS, which include type-2 diabetes and cardiovascular disease, can be treated 
with antidiabetic drugs and statins. (Uche Anadu Ndefo et al., 2013) 
Nonpharmacological Approaches because the primary cause of PCOS is unknown, 
treatment is directed at the symptoms. Few treatment approaches improve all 
aspects of the syndrome, and the patient’s desire for fertility may prevent her from 
seeking treatment despite the presence of symptoms. (Legro RS 1998) 
Treatment goals have to include regulating anovulation, inhibiting the action of 
androgens on target tissues, and reducing insulin resistance. Weight reduction for 
obese patients with PCOS is beneficial in many ways. Weight loss helps to 
decrease androgen, luteinizing hormone (LH), and insulin levels. It also helps to 
regulate ovulation, thereby improving the potential for pregnancy. (Guzick DS   
2004) 
As a safe and effective a non pharmacological mode of intervention, yoganidra can 
be utilized for polycystic ovarian syndrome justified by  the cost effective and 
availability of yoga in all over the world and YogaNidra  being concurrently 
effective and effortless practice, can be practiced by  everyone,  even  morbidly 
obese and those who are having  movement constraint or of limited physical 
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activity.Subjects  had significant result in weight reduction, effective management 
in long-term consequences of PCOS such as DM and cardiovascular diseases 
through regulating their blood sugar level and lipid profile to normal and also 
regulating sympathetic activity and HPA axis by coping stress in an effective way. 
This furthers the scope of expanding the research more concretely in the direction 
of non pharmacological mode of treatment for PCOS with a larger sample size. 
Pharmacologic versus a psychological intervention approach in the management of 
PCOS   a very reasonable question is: Why we need a psychological intervention in 
lieu of a pharmacological intervention, such as prescribing metformin to women 
with PCOS? (Blackburn IM and Moore RG 1997, Fava GA et al., 1998, Gould 
RA et al., 1995) 
In the management  of PCOS  treatment include behavioral and psychological 
interventions as adjunctive to standard medical care.It is very likely that clinicians 
already employ behavioral and psychological interventions (e.g., smoking cessation 
advice, addressing barriers to adherence, brief assessment of mood) in the absence 
of established guidelines. Research protocols could help establish whether these 
interventions are indeed effective in managing this chronic disorder. 
Given the evidence supporting relationships among physiological and 
psychological characteristics common in PCOS, and the existence of behavioral 
and/or psychological intervention approaches that result in improved metabolic, 
anthropometric, and reproductive parameters, some aims for future research might 
include the following: 
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• Investigate whether improvement in sleep quality specifically, reduction in sleep 
apnea among women with PCOS reduces not only physiological abnormalities 
such as visceral fat and inflammation but also improves other characteristics such 
as mood and ovulation rate. 
• Since muscle contractions stimulate glucose uptake in the absence of insulin and 
increased soleus muscle mass may reduce insulin resistance, future work should 
test whether yoga increases muscle mass and reduces insulin resistance in young 
women with PCOS. 
• Elucidate the behavioral and interpersonal goals that might motivate an 
adolescent who is newly diagnosed with PCOS to improve her lifestyle to achieve 
weight loss (via naturopathy and yogic management). 
Limitations: 
 USG can be done to assess the morphological changes among the PCOS 
patients for the impact of the YogaNidra.  
 Oxidative stress markers level along with lipid profile will be more ideal for 
assessing the effect of YogaNidra on PCOS.  
 Bio markers (Cortisol and amylase) level will be measured. 
 Large sample size with proper study design such as Randomized control 
trial will be more appropriate study design to evaluate the impact of 
YogaNidra.      
91 
 
7. SUMMARY AND CONCLUSION 
 PCOS is a common and chronic endocrine disorder characterized by 
hyperandrogenism, menstrual cycle abnormalities and polycystic ovaries and 
common cause of infertility and pregnancy complications. Development of PCOS 
appears to be spurred by a chronic state of insulin resistance cause defect in HPA 
axis and ovarian abnormalities that are likely `programmed to be dysfunctional 
very early in life. Increased insulin resistance is linked with decreased SHBG, 
consequences in increased bioavailable testosterone. Increased testosterone causes 
infertility and increased acne, alopecia, and hirsutism, and it also appears to be 
associated with an increased inflammatory state, mood disorders, and obesity. 
Women with PCOS also have a tendency to show signs of central obesity and 
increased visceral fat compared with non-PCOS women matched for BMI. This 
phenomenon could be due to an HPA axis defect such that women with PCOS have 
increased or abnormal cortisol responses to physical and psychological stressors. 
Central obesity alone does not fully explain the presence of insulin resistance or 
inflammation, as even lean women with PCOS show indication of insulin 
resistance and increased inflammatory markers, suggesting that these maladaptive 
physiological states are inherent among women with PCOS. Embarrassing PCOS 
symptoms such as acne, hirsutism, and central obesity appear during adolescence 
and significantly affect the well-being and mental health of the young woman 
during a phase in life in which she is expanding her social network and beginning 
to date. 
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PCOS alone and possibly appearance of its symptoms set the stage for 
development of emotional disturbances such as depression and social phobia. 
These emotional difficulties may, in turn, exacerbate already-existing obesity and 
other maladaptive physiological characteristics increased consumption of 
carbohydrates, smoking, reduced exercise) and physiological pathways, as 
previously discussed.Physiological and psychological abnormalities are more in 
women with PCOS are strongly interconnected. 
These relations suggest that management of PCOS would benefit significantly from 
inclusion of psychological and  or behavioral approaches and stress management 
intervention through higher stage of yoga that is YogaNidra (a form of 
prathyahara).This review presented the evidence supporting the robust relationships 
between physiological and psychological processes and physical and emotional 
symptoms in women with PCOS. To ease emotional disturbances might result in 
enhanced physiological processes with the result of improving insulin resistance, 
HPA axis functioning, obesity, and hyperandrogenism consequently, via the 
psychological-physiological pathways described hyperandrogenemic symptoms of 
PCOS might be alleviated, and the incidence and exacerbation of PCOS and its 
symptoms, especially among adolescents and also the long term consequences of 
PCOS. 
The present study suggests that YogaNidra can be safely and effectively used in the 
treatment of Polycystic ovarian syndrome justified by the cost effective and 
availability of yoga in all over the world and YogaNidra practice being 
concurrently effective and effortless, it can be practiced by everyone, even 
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morbidly obese and those who are having movement constraint or of limited 
physical activity. 
Subjects had significant result in weight reduction, effective management in long-
term consequences of PCOS such as DM and cardiovascular diseases through 
regulating their blood sugar level and lipid profile to normal and also regulating 
sympathetic activity and HPA axis by coping stress in an effective way.  
As YogaNidra concurrently address the mind and body it may be possible to attain 
the results safe and positive in a short span of time as a non - pharmacological 
intervention which deals with and recover all aspects of the syndrome assertively. 
Hence YogaNidra would be very much recommended as an effectual therapy 
which could replace rather than as an adjuvant with the available line of 
pharmacological management as PCOS women need long term treatment.  
This furthers the scope of expanding the research more concretely in the direction 
of non pharmacological mode of treatment for PCOS with a larger sample size. 
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9. ANNEXURES 
 
PERSONAL INFORMATION 
1.  Name 
2.  Age 
3.  Date of Birth 
4.  Address 
5.  Contact no 
  
ANTHROPOMETRIC MEASURES 
6.  Height (meters) 
7.  Weight (kilogram) 
8.  BMI (kg/m2) 
9.  Waist (centimeters) 
10.  Hip (centimeters) 
11.  Waist : Hip Ratio 
 CLINICAL SYMPTOMS 
12 Years since diagnosis 
13 
 
 
 
 
Cycle Characteristics Oligomenorrhea? 
Longest Amenorrhea? 
14 Acne Sites: 
 
 
 
 
 
 
 
 
 
 
 
Grade:          Mild /         Moderate /        Severe 
15 
 
 
Alopecia 
Grade:          Mild /        Moderate            Severe 
16 
 
 
 
 
 
 
Hirsutism Lip __________________________ 
Chin ________ 
Chest ________ 
Upper Abdomen ________ 
Lower Abdomen ________ 
Arms  ________ 
Thighs ________ 
Upper Back ________ 
Lower Back ________ 
TOTAL ________ 
 
 
 
INFORMED CONSENT FORM 
Title of the study: “Evaluation of effect of YogaNidra on biochemical changes in 
Polycystic ovarian syndrome women between the age of 18-35 years.”” 
Name of the Participant: 
Name of the Principal Investigator: Dr.A.Vanitha 
Name of the Institution: 
Government Yoga and Naturopathy Medical College (GYNMC) 
Arumbakkam, Chennai - 600106 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been answered. I 
am over 18 years of age and, exercising my free power of choice, hereby give my 
consent to be included as a participant in “Evaluation of effect of YogaNidra on 
biochemical changes in Polycystic ovarian syndrome women between the age of 
18-35 years.” 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past ________ months including any native (alternative) treatment. 
 
 
 
 
 
6. I have been advised about the risks associated with my participation in this study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately if 
I suffer unusual symptoms. 
8. I have not participated in any research study within the past _________month(s). 
9. I am aware of the fact that I can opt out of the study at any time without having to 
give 
any reason and this will not affect my future treatment in this hospital. 
10. I am also aware that the investigator may terminate my participation in the study 
at any time, for any reason, without my consent. 
12. I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory authorities, 
Govt. agencies, and IEC. I understand that they are publicly presented. 
13. I have understood that my identity will be kept confidential if my data are 
publicly presented.  
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document. 
 
 
 
 
 
 
For adult participants: 
Name and signature / thumb impression of the participant (or legal 
representative if 
participant incompetent) 
Name _________________________ Signature_________________ 
Date________________ 
 
 
Name and Signature of impartial witness (required for illiterate patients): 
Name _________________________ Signature_________________ 
Date________________ 
Address and contact number of the impartial witness: 
 
 
Name and Signature of the investigator or his representative obtaining consent: 
Name _________________________ Signature_________________ 
Date________________ 
 
 
 
 
 
 
 
 
 
ஆராய்ச்சி ஒப்புதல் படிவம் 
ஆய்வு தலைப்பு : --------------- 
ஆராய்ச்சியாளர் பெயர் : மரு.ஆ.வனிதா 
ஆராய்ச்சி நடக்கும் இடம்: 
ெங்கு பெறுெவரின் பெயர்:    வயது: 
ொைினம்:  ஆண் / பெண்      
ெங்கு பெறுெவரின்அலடயாள எண் 
இந்த ஆராய்ச்சியின் விவரங்களும் அதன் நநாக்கமும் 
முழுலமயாக பதளிவாக எனக்கு விளக்கப்ெட்டது. 
எனக்கு விளக்கப்ெட்ட தகவல்கலள புரிந்து பகாண்டு நான் எனது 
சம்மதத்லதத் பதரிவிக்கிநேன். 
நான் நமற்குேிப்ெிட்ட ஆராய்ச்சியில் ெங்குபெற்று   ெரிநசாதலன 
நமற்பகாள்ளவும் முழு சம்மதம் பதரிவிக்கிநேன். 
 
 
 
 
 
 
 
 
இந்த ஆராய்ச்சியில் இருந்து நான் எந்த நநரமும் ெின்வாங்கைாம் 
என்றும் அதனால் எந்த ொதிப்பும் ஏற்ெடாது என்ெலதயும் புரிந்து 
பகாண்நடன். 
நான் நயாகநித்ரா ஆராய்ச்சியின் தகவல்கலள  பெற்று 
பகாண்நடன். 
நான் என்னுலடய சுயநிலனவுடனும்முழு சம்மதத்துடனும் 
ஆராய்ச்சியில் என்லன ெரிநசாதிக்க சம்மதிக்கிநேன். 
 
 
ஆராய்ச்சியாளர் லகபயாப்ெம்:  ெங்கு பெறுெவர் 
லகபயாப்ெம்  / 
 
நததி :       இடதுலக பெருவிரல் 
நரலக 
 
 
  
 
 
 
 
ஆராய்ச்சி தகவல் தாள் 
ஆய்வு தலைப்பு : 
ெங்கு பெறுெவரின் பெயர்:    வயது: 
ொைினம்:  ஆண் / பெண்      
ெங்கு பெறுெவரின்அலடயாள எண்: 
அரசு நயாகா மற்றும் இயற்லக மருத்துவ கல்லூரி 
மருத்துவமலனயில் நயாகநித்ரா  ெயிற்சியின் மூைம் 
சிலனப்லெ நீர்கட்டிகளுலடய மகளிர் உடைில் ஏற்ெடும் 
உயிர்நவதியியல் மாற்ேங்கலள அேியும் ஆராய்ச்சி இங்கு 
நலடப்பெறுகிேது. 
நயாகநித்ரா  ெயிற்சி மனித உடைில் ஏற்ெடுத்தும் 
மாற்ேங்கலள அேிவதன் மூைம் ,சிலனப்லெ 
நீர்கட்டிகளுலடய  ( PCOS ) மகளிர் உடைில் அந்நநாயினால் 
ஏற்ெடும் நீண்ட நாள் ொதிப்புகளான சர்க்கலர நநாய் மற்றும் 
இருதய நநாய்  ொதிப்புகளிைிருந்து மகளிலர காக்க இயலும் 
.நீங்கள் இந்த ஆய்வில் ெங்நகற்று ஒத்துலைப்பு நல்கிட 
 
 
 
நாங்கள் விரும்புகிநோம். இதில் உங்களுலடய ரத்த சர்க்கலர 
அளவு , உடல் நிலே குேியடீு எண், நாடி, ரத்த அழுத்தம் 
ெரிநசாதிக்கப்ெடும். இதனால் தங்களுலடய அன்ோட 
பசயல்ொடுகள் ொதிக்கப்ெடாது என்று 
பதரிவித்துபகாள்கிநோம். 
முடிவுகலளயும் கருத்துகலளயும் பவளியிடும் நொநதா அல்ைது 
ஆராய்ச்சியின் நொநதா தங்கள் பெயலரநயா 
அலடயாளங்கலளநயா பவளியிட மாட்நடாம் என்ெலதயும் 
பதரிவித்துக் பகாள்கிநோம். 
இந்த சிேப்பு ெரிநசாதலனகளின் முடிவுகள் ஆராய்ச்சியின் நொது 
அல்ைது  அதன் முடிவில் அேிவிக்கப்ெடும் என்ெலதயும் 
பதரிவித்து பகாள்கிநோம். 
இந்த ஆராய்ச்சியில் ெங்நகற்ெது தங்களுலடய விருப்ெத்தின் 
நெரில் ஆகும்.நமலும் நீங்கள் இந்த ஆராய்ச்சியில் இருந்து எந்த 
நநரமும் ெின்வாங்கைாம் என்ெலத பதரிவித்து பகாள்கிநோம். 
மரு .அ ..வனிதா +91-  8428859927 vanitha.rajii@gmail.com 
